[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 273
1. Schütt P, Zimmermann K, Derks C, Ebeling P, Welt A, Poser M, Hense J, Metz K, Anhuf J, Sandmann M, Neise M, Moritz T, Stuschke M, Niederle N, Seeber S, Nowrousian MR: Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma. J Cancer Res Clin Oncol; 2009 Mar;135(3):459-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.
  • INTRODUCTION: Anthracyline-based chemotherapy is the treatment of choice for patients with aggressive B-cell non-Hodgkin's lymphoma (NHL).
  • Consolidating involved-field irradiation was applied in patients with stage I/II, bulky disease, or localized residual lymphoma.
  • Main toxicity was grade 3/4 leukocytopenia in 89% patients with neutropenic fever in 30%.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal / toxicity. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Remission Induction. Rituximab. Survival Analysis. Survivors. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):257-67 [8558207.001]
  • [Cites] Ann Intern Med. 1990 Oct 15;113(8):619-27 [2205142.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1067-73 [11583187.001]
  • [Cites] Cancer Res. 1986 Jul;46(7):3722-7 [3458531.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):536-41 [16098067.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1864-71 [15143078.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2070-9 [9626206.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):277-81 [12562656.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2912-9 [16339404.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3776-85 [10577849.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):614-22 [16423847.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):93-101 [17313557.001]
  • [Cites] Tumori. 2007 Sep-Oct;93(5):409-16 [18038870.001]
  • [Cites] Ann Oncol. 1993 May;4(5):359-69 [8353070.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • (PMID = 18758815.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


2. Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, Trümper LH, Meller J, Pfreundschuh M, Kirsch CM, Naumann R, Kropp J, Horne H, Teoh N, Le Gouill S, Bodet-Milin C, Chatal JF, Goldenberg DM: High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol; 2010 Aug 10;28(23):3709-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
  • PURPOSE: Fractionated radioimmunotherapy targeting CD22 may substantially improve responses and outcome in non-Hodgkin's lymphoma (NHL).
  • RESULTS: At the maximum total (90)Y dose of 45 mCi/m(2) (1,665 MBq/m(2)), grade 3 to 4 hematologic toxicities were reversible to grade 1 in patients with less than 25% bone marrow involvement.
  • For patients with follicular lymphoma (FL), OR rates and median PFS increased with total (90)Y-dose, reaching 100% (CR/CRu, 92%) and 24.6 months, respectively, at the highest dose levels (> 30 mCi/m(2) total (90)Y-dose [1,110 MBq/m(2)]).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy. Yttrium Radioisotopes / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Yttrium Radioisotopes; 0 / epratuzumab
  •  go-up   go-down


3. Vassallo J, Bousquet M, Quelen C, Al Saati T, Delsol G, Brousset P: CD5-positive diffuse large B cell lymphoma arising from a CD5-positive follicular lymphoma. J Clin Pathol; 2007 May;60(5):573-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD5-positive diffuse large B cell lymphoma arising from a CD5-positive follicular lymphoma.
  • Follicular lymphoma (FL) is a neoplasm originating from germinal centre cells, corresponding to 25-40% of non-Hodgkin's lymphomas.
  • Transformation into diffuse large B cell lymphoma (DLBCL) occurs in about one-third of cases.
  • CD5 is expressed in B-chronic lymphoid leukaemia/small lymphocytic lymphoma and mantle cell lymphoma, but can rarely be expressed in conjunction with CD10 in well-documented cases of FL.
  • In this report one case of grade 1 FL is described, which transformed into a DLBCL 6 months after initial diagnosis, with both tumours expressing CD5.
  • [MeSH-major] Antigens, CD5 / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm / metabolism. Disease Progression. Female. Humans

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):1-11 [10937042.001]
  • [Cites] Am J Clin Pathol. 2005 Aug;124(2):182-90 [16040287.001]
  • [Cites] Am J Clin Pathol. 2000 Dec;114(6):912-21 [11338480.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jul;125(7):951-3 [11419985.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):291-300 [11863226.001]
  • [Cites] Am J Clin Pathol. 2002 Oct;118(4):589-98 [12375647.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):218-30 [12579992.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Nov;36(11):2105-11 [15313456.001]
  • [Cites] J Clin Pathol. 1992 Nov;45(11):1018-22 [1280654.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Br J Haematol. 1996 Sep;94(4):676-84 [8826892.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):16-21 [9059349.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] Mol Pathol. 1998 Dec;51(6):333-8 [10193514.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1269-79 [11144922.001]
  • (PMID = 17513519.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Antigens, Neoplasm
  • [Other-IDs] NLM/ PMC1994527
  •  go-up   go-down


Advertisement
4. Piccaluga PP, Califano A, Klein U, Agostinelli C, Bellosillo B, Gimeno E, Serrano S, Solè F, Zang Y, Falini B, Zinzani PL, Pileri SA: Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica; 2008 Jul;93(7):1033-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND METHODS: We studied the gene expression profile of 43 follicular lymphomas, 50 B-cell non-Hodgkin's lymphomas of different histotype, and 20 samples of normal B-lymphocytes in order to assess: (i) the relationship of follicular lymphoma with normal B cells and other B-cell non-Hodgkin's lymphomas;.
  • (ii) whether follicular lymphoma is a unique disease; and (iii) whether follicular lymphoma grade IIIb is closer to follicular lymphoma or diffuse large B-cell lymphoma of the germinal center B-cell type.
  • RESULTS: First, we found that the molecular profile of follicular lymphoma is intimately related to that of normal germinal center B cells, irrespectively of the histological grade.
  • Secondly, we observed that follicular lymphoma has a relatively homogeneous gene expression profile that is distinct from that of other B-cell non-Hodgkin's lymphoma and does not include discrete molecular subgroups.
  • However, by further clustering samples according to signatures differentially expressed among follicular lymphomas or in follicular lymphomas versus diffuse large B-cell lymphoma, we showed that grade I-IIIa tumors tend to cluster together, while grade IIIb follicular lymphoma constitutes a distinct subgroup, whose molecular signature is closer to that of the remaining follicular lymphomas than to that of diffuse large B-cell lymphoma of the germinal center B-cell type.
  • CONCLUSIONS: These data support the hypothesis that grade IIIb follicular lymphoma does indeed belong to the group of follicular lymphomas rather than diffuse large B-cell lymphomas, and also suggests a possible revision of the histological grading of follicular lymphomas, with their simple distinction into follicular lymphoma (grade I-IIIa) and follicular lymphoma/large cell (grade IIIb).
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / genetics. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adult. Aged. Cluster Analysis. Female. Genome, Human. Humans. Male. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492688.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


5. Yamamoto S, Nakase H, Yamashita K, Matsuura M, Takada M, Kawanami C, Chiba T: Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol; 2010 Apr;45(4):370-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal follicular lymphoma: review of the literature.
  • Gastrointestinal follicular lymphoma (GI-FL) is a relatively rare disease, accounting for only 1%-3.6% of gastrointestinal non-Hodgkin's lymphoma.
  • FL is a low-grade lymphoma that usually develops very slowly.
  • If the lymphoma causes no symptoms, immediate treatment may not be necessary.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / therapy. Lymphoma, Follicular / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Kyoto University Research Information Repository - Articles. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 May;128(6):1579-605 [15887153.001]
  • [Cites] Int J Gastrointest Cancer. 2005;36(2):113-9 [16648662.001]
  • [Cites] Blood. 2000 Feb 1;95(3):783-9 [10648386.001]
  • [Cites] Ann Oncol. 2006 May;17 (5):780-4 [16497824.001]
  • [Cites] Leukemia. 1993 Feb;7(2):268-73 [8426481.001]
  • [Cites] Dig Dis Sci. 2001 Mar;46(3):567-70 [11318534.001]
  • [Cites] Dig Dis Sci. 2007 Apr;52(4):1031-5 [17353993.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1355-61 [18684042.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):432-9 [11295923.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E86-7 [17440873.001]
  • [Cites] Histopathology. 1984 Jul;8(4):641-56 [6479906.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:249-57 [13695582.001]
  • [Cites] Intern Med. 2007;46(3):141-2 [17268132.001]
  • [Cites] Recent Results Cancer Res. 2000;156:116-24 [10802871.001]
  • [Cites] J Mol Diagn. 2007 Sep;9(4):530-7 [17652637.001]
  • [Cites] N Engl J Med. 1987 Jan 8;316(2):79-84 [3537802.001]
  • [Cites] Hepatogastroenterology. 2007 Sep;54(78):1658-61 [18019688.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):105-13 [12507894.001]
  • [Cites] J Clin Pathol. 2008 Mar;61(3):377-81 [17601964.001]
  • [Cites] J Clin Gastroenterol. 2008 Oct;42(9):997-1002 [18719510.001]
  • [Cites] Gastrointest Endosc. 2008 Apr;67(4):763-5 [18207144.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1563-9 [10995001.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):408-10 [12902896.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Can J Gastroenterol. 1997 Jan-Feb;11(1):31-4 [9113795.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):735-44 [11298531.001]
  • [Cites] Histopathology. 2005 Nov;47(5):467-78 [16241994.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jan;21(1):17-29 [9443038.001]
  • [Cites] Mod Pathol. 2000 May;13(5):586-90 [10824932.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8018-24 [16204012.001]
  • [Cites] Endoscopy. 2009 Feb;41(2):175-8 [19214900.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):442-52 [8604811.001]
  • [Cites] Br J Haematol. 2004 Sep;126(6):772-84 [15352980.001]
  • [Cites] Am J Pathol. 1992 Jun;140(6):1327-35 [1376556.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Aug;5(8):e30 [17625984.001]
  • [Cites] Histopathology. 1998 Feb;32(2):116-25 [9543667.001]
  • [Cites] Ann Hematol. 2004 May;83(5):276-8 [15060746.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):484-8 [9130997.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):614-7 [12461620.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Feb;33(2):213-6 [11793448.001]
  • [Cites] Endoscopy. 2008 Apr;40(4):343-6 [18067068.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3922-8 [10845929.001]
  • [Cites] Ann Hematol. 2002 Apr;81(4):228-31 [11976827.001]
  • [Cites] Gut. 2003 Jun;52 Suppl 4:iv48-50 [12746269.001]
  • [Cites] Haematologica. 1992 Mar-Apr;77(2):156-61 [1398301.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):1083-100 [15488559.001]
  • [Cites] Gastrointest Endosc. 2001 Jul;54(1):92-6 [11427853.001]
  • [Cites] Springer Semin Immunopathol. 1990;12(2-3):239-50 [2205943.001]
  • [Cites] Mod Pathol. 2009 Jul;22(7):940-9 [19396151.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Nov;5(11):A24 [17981239.001]
  • [Cites] Intern Med. 2007;46(11):705-9 [17541220.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):652-9 [17582800.001]
  • [Cites] Histopathology. 2004 Mar;44(3):268-76 [14987231.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):175-83 [16721817.001]
  • [Cites] Eur J Cancer. 1991;27(10):1201-8 [1835586.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]
  • [Cites] Acta Oncol. 2001;40(2-3):213-23 [11441933.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]
  • [Cites] J Clin Gastroenterol. 2002 Feb;34(2):155-9 [11782611.001]
  • [Cites] Clin Transl Oncol. 2007 Jul;9(7):471-2 [17652063.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Science. 1985 Jun 21;228(4706):1440-3 [3874430.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E26-7 [17285496.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2456-64 [9310498.001]
  • [Cites] Arch Pathol Lab Med. 2004 Sep;128(9):1035-8 [15335250.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):218-24 [8426197.001]
  • [Cites] Hum Pathol. 1999 May;30(5):581-7 [10333231.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Hematol Oncol. 1983 Apr-Jun;1(2):187-92 [6376315.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):793-800 [11843811.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5 [9308704.001]
  • [Cites] Gastrointest Endosc. 2009 Jan;69(1):158-9; discussion 159 [19111697.001]
  • [Cites] J Clin Oncol. 1986 Oct;4(10):1470-80 [3531422.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):875-83 [11420458.001]
  • [Cites] Endoscopy. 2010 Jan;42(1):86; author reply 87 [20066597.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1556; author reply 1556-7 [14628813.001]
  • [Cites] J Mol Diagn. 2003 Aug;5(3):168-75 [12876207.001]
  • [Cites] Blood. 1986 Oct;68(4):837-45 [3530348.001]
  • [Cites] Blood. 2002 May 15;99(10):3806-12 [11986240.001]
  • [Cites] J Exp Med. 1986 Jul 1;164(1):315-20 [3014037.001]
  • [Cites] Intern Med. 2006;45(5):309-11 [16596000.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1641-9 [11117785.001]
  • [Cites] Pathol Res Pract. 2007;203(9):691-4 [17643847.001]
  • [Cites] Jpn J Clin Oncol. 2008 Aug;38(8):547-52 [18687756.001]
  • [Cites] Cell. 1986 Oct 10;47(1):19-28 [2875799.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Am J Surg Pathol. 1983 Jun;7(4):363-72 [6869665.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Gastroenterol. 2002 Sep;35(3):285-6 [12192212.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E39 [17285511.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1046-51 [9831200.001]
  • [Cites] Science. 1968 Dec 20;162(3860):1396-7 [4177362.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] World J Gastroenterol. 2004 Sep 1;10(17):2602-4 [15300917.001]
  • [Cites] J Gastroenterol. 2003;38(6):584-7 [12856675.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):365-72 [17134735.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):743-8 [11251169.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Cell. 1985 Jul;41(3):899-906 [3924412.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Intern Med. 2008;47(13):1277-8 [18591856.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1852-6 [12200703.001]
  • [Cites] Br J Surg. 1961 Jul;49:80-9 [13884035.001]
  • [Cites] J Gastroenterol. 2003;38(5):512-3 [12768397.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E8-9 [18278712.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2499-505 [10561315.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • (PMID = 20084529.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 126
  •  go-up   go-down


6. Diamond C, Taylor TH, Im T, Anton-Culver H: Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma; 2006 Sep;47(9):1822-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS.
  • We used the San Diego/Orange County cancer registry to identify 64 cases of systemic non-Hodgkin's lymphoma (NHL) with AIDS who received highly active antiretroviral therapy (HAART) at the time of NHL diagnosis or thereafter and 64 NHL controls without AIDS, matched on age, sex, race, time of NHL diagnosis (1994-1995 and 1996-1999), and hospital type (academic, large community, and small community).
  • Thirty-three percent of cases had high grade histology versus 11% of controls (p < 0.01); 69% had baseline hemoglobin <13 g/dL versus 35% controls (p < 0.001) and 21% had baseline neutrophils <2,000/mcl versus 4% of controls (p < 0.001).
  • Patients with AIDS-related NHL who received HAART had high grade histology and baseline cytopenia and received reduced-dose chemotherapy more often than patients without AIDS.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. CD4 Lymphocyte Count. Case-Control Studies. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome


7. Jacobs SA, Vidnovic N, Joyce J, McCook B, Torok F, Avril N: Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res; 2005 Oct 1;11(19 Pt 2):7146s-7150s
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Targeted radioimmunotherapy with yttrium-90 (90Y)-labeled ibritumomab tiuxetan (Zevalin, IDEC-Biogen, San Diego, CA) has shown significant activity in the treatment of relapsed or refractory CD20+ non-Hodgkin's lymphoma.
  • EXPERIMENTAL DESIGN: Eight patients with CD20+ non-Hodgkin's lymphoma had extensive prior therapy including myeloablative chemotherapy but did not receive total body irradiation.
  • RESULTS: Toxicities observed included grade 4 thrombocytopenia in three of eight evaluable patients and grade 4 neutropenia in one of eight evaluable patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy / methods. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Aged. Antigens, CD20 / biosynthesis. Blood Platelets / metabolism. Clinical Trials as Topic. Female. Fluorodeoxyglucose F18. Humans. L-Lactate Dehydrogenase / metabolism. Male. Middle Aged. Platelet Count. Pleural Effusion / pathology. Positron-Emission Tomography. Recurrence. Time Factors. Tomography, X-Ray Computed / methods. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203814.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


8. Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E: Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol; 2005 Jul 1;23(19):4372-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
  • PURPOSE: Primary effusion lymphoma (PEL) is a rare high-grade B-cell non-Hodgkin's lymphoma associated with Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) infection, and is mostly observed in the course of HIV infection.
  • To date, no prognostic factor has been identified in this subset of lymphoma.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Herpesvirus 8, Human. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Acquired Immunodeficiency Syndrome. Adult. Aged. Ascites / complications. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pericardial Effusion / complications. Pleural Effusion, Malignant / complications. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome


9. Economopoulos T, Papageorgiou S, Dimopoulos MA, Pavlidis N, Tsatalas C, Symeonidis A, Foudoulakis A, Pectasides D, Rontogianni D, Rizos E, Chalkia P, Anagnostopoulos A, Melachrinou M, Papageorgiou E, Fountzilas G: Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases. Acta Haematol; 2005;113(2):97-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases.
  • The purpose of this retrospective study, the largest unselected series in our country, was to illustrate the clinicopathological features of non-Hodgkin's lymphoma (NHL) classified according to the World Health Organization (WHO) classification of lymphoid neoplasms.
  • Among indolent lymphomas extranodal ones (MALT B cell lymphoma) were the most common subset while follicular lymphoma grade I and II and small lymphocytic ones presented with equal frequency.
  • Among the aggressive lymphomas diffuse large cell lymphoma (DLCL) was the most common subtype; this entity along with large-cell immunoblastic lymphomas accounted for 45.2% of all B cell lymphomas.
  • The frequency of follicular lymphoma in the current study is comparable to that reported from Asian countries and mainland Europe, but lower than that of US and Northern European series.
  • [MeSH-major] Gastrointestinal Neoplasms / classification. Head and Neck Neoplasms / classification. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, T-Cell, Peripheral / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Greece / epidemiology. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. World Health Organization

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel
  • (PMID = 15802887.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


10. Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B, German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL): Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Cancer; 2006 Jan 1;106(1):136-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
  • BACKGROUND: Patients with aggressive lymphoma and high-risk features at the time of diagnosis are reported to have a poor prognosis with standard therapy.
  • In the current study, the authors increased the doses and dose intensity of drugs used for the conventional first-line therapy of aggressive lymphoma and designed a Phase II randomized trial that compared four and six courses of dose-escalated CHOP plus etoposide (megaCHOEP) supported by the transplantation of peripheral blood stem cells.
  • METHODS: Eighty-four patients age < 60 years with aggressive lymphoma and elevated lactate dehydrogenase (LDH) levels were randomized to receive either 4 (Arm A) or 6 (Arm B) courses of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (megaCHOEP).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Antigens, CD34 / immunology. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prospective Studies. Survival Rate. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16331635.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


11. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol; 2008 Oct 20;26(30):4952-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
  • PURPOSE: The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy.
  • Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL).
  • The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL.
  • Responses were observed in each aggressive histologic subtype tested (diffuse large B-cell, follicular center grade 3, mantle cell, and transformed lymphomas).
  • The most common grade 4 adverse events were neutropenia (8.2%) and thrombocytopenia (8.2%); the most common grade 3 adverse events were neutropenia (24.5%), leukopenia (14.3%), and thrombocytopenia (12.2%).
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Male. Middle Aged. Prospective Studies. Remission Induction


12. Kanat O, Ozet A, Ataergin S, Arpaci F, Kuzhan O, Komurcu S, Ozturk B, Ozturk M: Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma. Med Princ Pract; 2010;19(5):344-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma.
  • OBJECTIVE: Our purpose was to investigate the efficacy of and establish a toxicity profile for a modified regimen of dexamethasone, cytarabine and cisplatin (DHAP) for lymphoma outpatients.
  • SUBJECTS AND METHODS: Fifty-one lymphoma patients, 26 with Hodgkin's disease and 25 with non-Hodgkin's lymphoma, were included.
  • WHO grade III-IV neutropenia and grade III-IV thrombocytopenia were observed in 27 (52.9%) and 21 (41%) patients, respectively.
  • The overall response rate (85% for Hodgkin's disease and 95% for non-Hodgkin's lymphoma) was 88.3% (39.2% complete response and 49.1% partial response).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Outpatients
  • [MeSH-minor] Adolescent. Adult. Cisplatin / adverse effects. Cisplatin / therapeutic use. Cytarabine / adverse effects. Cytarabine / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20639655.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


13. Basu D, Yaranal PJ, Kalyan K, Soundararaghavan J: Mantle cell lymphoma--a clinicopathological study of 13 cases. Malays J Pathol; 2005 Jun;27(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma--a clinicopathological study of 13 cases.
  • Mantle cell lymphoma is an uncommon non-Hodgkin's lymphoma.
  • In a period of four years, 13 cases of mantle cell lymphoma were diagnosed in our department, comprising 3.1% of all non-Hodgkin's lymphoma diagnosed.
  • Despite certain morphological similarity to other low-grade lymphomas, mantle cell lymphoma has a characteristic appearance of its own.
  • It is more aggressive than other low-grade lymphomas and hence needs to be accurately diagnosed.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / immunology. Biopsy, Needle. Bone Marrow Examination. Cyclin D1 / immunology. Female. Humans. Immunohistochemistry. Immunophenotyping. Lymph Node Excision / statistics & numerical data. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16676688.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Antigens, CD20; 136601-57-5 / Cyclin D1
  •  go-up   go-down


14. Huang HQ, Lin XB, Pan ZH, Bu Q, Gao Y, Wang BF, Cai QQ, Xia ZJ, Xu RH, Jiang WQ, Guan ZZ: [CEOP regimen in the treatment for non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2007 May;29(5):391-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
  • OBJECTIVE: The aim of this study is to analyse the efficacy and toxicity of CEOP regimen in the treatment of non-Hodgkin's lymphoma (NHL).
  • Major toxicity consisted of grade III-IV myelosuppression (11.9%), neutropenia (1.9%) and thrombocytopenia and anemia (1.1%).
  • CONCLUSION: Our data show that CEOP regimen combined with or without radiotherapy for the involved field is effective and well tolerated by the patients with non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Child. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Epirubicin / adverse effects. Epirubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / adverse effects. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Analysis. Thrombocytopenia / chemically induced. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892140.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  •  go-up   go-down


15. Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R: Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol; 2006 Apr 1;24(10):1590-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
  • PURPOSE: To compare the efficacy and safety of fludarabine phosphate with cyclophosphamide, vincristine, and prednisone (CVP) in 381 previously untreated, advanced-stage, low-grade (lg) non-Hodgkin's lymphoma (NHL) patients in a phase III, multicenter study.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine Phosphate / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / therapeutic use. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prospective Studies. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 106XV160TZ / Vidarabine Phosphate; 1X9VK9O1SC / fludarabine phosphate; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


16. Song H, Du Y, Sgouros G, Prideaux A, Frey E, Wahl RL: Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med; 2007 Jan;48(1):150-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
  • Pulmonary involvement is common in patients with non-Hodgkin's lymphoma (NHL). (90)Y- and (131)I-anti-CD20 antibodies (ibritumomab tiuxetan and tositumomab, respectively) have been approved for the treatment of refractory low-grade follicular NHL.
  • METHODS: Lung metastases were simulated as spheres, with radii ranging from 0.2 to 5.0 cm, which were randomly distributed in a voxelized adult male lung phantom.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2006 Dec;47(12):1985-94 [17138741.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2934-42 [11049969.001]
  • [Cites] J Nucl Med. 2001 Jun;42(6):967-74 [11390564.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3186-92 [11595713.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):165-72 [15023434.001]
  • [Cites] Med Phys. 2000 Jul;27(7):1555-62 [10947258.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1259-66 [10942366.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7565-73 [16186600.001]
  • [Cites] Pediatr Radiol. 2004 Feb;34(2):120-4 [14605781.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):145-55 [14716739.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2351-7 [12750161.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):111-8 [12517786.001]
  • [Cites] J Nucl Med. 2002 Nov;43(11):1507-29 [12411555.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1316-23 [10715303.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):327-37 [14960657.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):1023-7 [15937315.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S [15653661.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3270-8 [9779701.001]
  • [Cites] Cancer. 1997 Dec 15;80(12 Suppl):2636-41 [9406718.001]
  • [Cites] Int J Cancer. 1997 Jul 29;72(3):477-85 [9247292.001]
  • [Cites] Phys Med Biol. 1996 Oct;41(10):1871-84 [8912367.001]
  • [Cites] Leuk Lymphoma. 1996 Jan;20(3-4):229-37 [8624461.001]
  • [Cites] N Engl J Med. 1993 Oct 21;329(17):1219-24 [7692295.001]
  • [Cites] J Nucl Med. 1993 Mar;34(3):448-54 [8441037.001]
  • [Cites] J Nucl Med. 2004 Jul;45(7):1224-32 [15235070.001]
  • (PMID = 17204712.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116477-01A1; United States / NCI NIH HHS / CA / R01 CA116477; United States / NCI NIH HHS / CA / R01 CA116477-01A1; United States / NCI NIH HHS / CA / R01CA116477
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes
  • [Other-IDs] NLM/ NIHMS246413; NLM/ PMC2967041
  •  go-up   go-down


17. Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A, Loeffler M, Trümper L, Pfreundschuh M, Siebert R, German High-Grade Non-Hodgkin's Lymphoma Study Group: Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia; 2008 Dec;22(12):2226-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
  • Recent retrospective studies of heterogeneously treated patients have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL).
  • Here, we investigated the prognostic impact of MYC aberrations analyzed by interphase fluorescence in situ hybridization in 177 patients with de novo DLBCL treated within the two prospective, randomized trials non-Hodgkin's lymphoma NHL-B1 and NHL-B2.
  • [MeSH-major] Chromosome Aberrations. Gene Expression Regulation, Neoplastic. Genes, myc / genetics. Lymphoma, Large B-Cell, Diffuse
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Germany / epidemiology. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Randomized Controlled Trials as Topic. Retrospective Studies. Risk Factors. Young Adult


18. Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N: Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest; 2008 May;26(4):401-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
  • BACKGROUND: High dose chemotherapy with autologous stem cell transplantation is currently the treatment of choice for relapsed or refractory lymphoma patients.
  • In this study, our aim was to compare the efficacy and toxicity profiles of DHAP (cytosine arabinoside, cisplatin and dexamethasone) and ICE (ifosfamide, carboplatin and etoposide) regimens in the salvage treatment of relapsed and refractory lymphoma.
  • PATIENTS AND METHODS: In this retrospective analysis, 53 patients with primary refractory or relapsed Hodgkin's disease (HD) (n = 13) or non-Hodgkin lymphoma (NHL) (n = 40) who received ICE or DHAP salvage regimen were included.
  • The major grade III-IV toxicities for both groups were hematological (neutopenia and thrombocytopenia).
  • The main non-hematological toxicity was renal and observed in 8 patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Carboplatin / administration & dosage. Carboplatin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cohort Studies. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Immunotherapy. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Recurrence. Remission Induction. Retrospective Studies. Rituximab. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443961.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; DHAP protocol; ICE protocol 3
  •  go-up   go-down


19. Ahn JS, Park S, Im SA, Yoon SS, Lee JS, Kim BK, Bang SM, Cho EK, Lee JH, Jung CW, Kim HC, Seong CM, Lee MH, Kim CS, Lee KS, Lee JA, Ahn MJ: High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization. Korean J Intern Med; 2005 Sep;20(3):224-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To compare the mobilizing effects and toxicities of two different doses of cyclophosphamide (CY) plus lenograstim (glycosylated G-CSF), we performed a prospective randomized study by enrolling patients suffering with either high-risk Non-Hodgkin's lymphoma (NHL) or breast cancer undergoing ablative chemotherapy.
  • Grade III or IV leukopenia was present in 14/15 patients (94%) in arm A and in 1/12 patients (8%) in arm B (p<0.0001).
  • Grade Ill or IV thrombocytopenia was present in 8/15 patients (54%) in arm A, but this was not present in any patients of arm B (p=0.0004).
  • [MeSH-major] Breast Neoplasms / drug therapy. Cyclophosphamide / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Lymphoma, Non-Hodgkin / drug therapy. Myeloablative Agonists / administration & dosage. Stem Cells / drug effects
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Drug Therapy, Combination. Female. Humans. Leukapheresis. Male. Middle Aged. Prospective Studies. Recombinant Proteins / administration & dosage. Recombinant Proteins / pharmacology. Transplantation Conditioning

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1360-77 [10715309.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2863-92 [9376567.001]
  • [Cites] Bone Marrow Transplant. 2000 Jun;25(11):1141-6 [10849526.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2059-64 [11567990.001]
  • [Cites] Ther Apher. 2002 Feb;6(1):5-14 [11886571.001]
  • [Cites] Bone Marrow Transplant. 2002 Feb;29(4):285-90 [11896424.001]
  • [Cites] Transfusion. 2003 Jan;43(1):50-7 [12519430.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1693-702 [7518861.001]
  • [Cites] Bone Marrow Transplant. 1994 Nov;14(5):827-32 [7534163.001]
  • [Cites] Blood Cells. 1994;20(2-3):364-9; discussion 369-70 [7538340.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1922-32 [7543561.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):586-92 [8636775.001]
  • [Cites] Transfusion. 1996 Jul;36(7):611-24 [8701456.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):535-46 [9053475.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(4):331-6 [9051242.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2233-58 [9116266.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2312-21 [9196145.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2882-93 [9256132.001]
  • [Cites] Bone Marrow Transplant. 1997 Oct;20(7):587-91 [9337061.001]
  • [Cites] Blood. 1997 Nov 15;90(10):3844-52 [9354650.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1824-30 [10784622.001]
  • (PMID = 16295781.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6WS4C399GB / lenograstim; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC3891157
  •  go-up   go-down


20. Morris E, Mackinnon S: Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfus Apher Sci; 2005 Feb;32(1):73-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL).
  • Grade III-IV acute GVHD developed in 4 patients and chronic GVHD in 6 patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Recurrence. Time Factors. Transplantation Chimera. Transplantation Conditioning. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737876.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


21. Bhurgri Y, Pervez S, Bhurgri A, Faridi N, Usman A, Kazi LA, Ahmed R, Kayani N, Hasan SH: Increasing incidence of non-Hodgkin's lymphoma in Karachi, 1995-2002. Asian Pac J Cancer Prev; 2005 Jul-Sep;6(3):364-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing incidence of non-Hodgkin's lymphoma in Karachi, 1995-2002.
  • This first population-based study of non- Hodgkin lymphoma (NHL) from any region in Pakistan, provides an overview of the incidence pattern and time trends in Karachi and generates hypotheses for future experimental research.
  • The adult to childhood ratios were 8.6 (M) and 10.7 (F).
  • The incidence rates of NHL registered in Karachi South are likely to be a reflection of non-AIDS-associated NHL.
  • The preponderance of low and intermediate grade lymphomas, paucity of central nervous system NHL and a higher childhood NHL component support this hypothesis.
  • NHL correlation with HIV/AIDS status and studies identifying risk factors of non- HIV/AIDS associated NHL (childhood viral infections, Hepatitis C virus, and Helicobacter pylori) are potential areas for future experimental and epidemiological research.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Registries / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Epidemiologic Studies. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Pakistan / epidemiology. Sex Factors

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236001.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


22. Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA: Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol; 2006 May 01;24(13):2105-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
  • Twenty-four patients had mantle cell lymphoma (MCL), 13 had follicular lymphoma (FL), six had lymphoplasmacytic lymphoma, six had Hodgkin's disease (HD), and one each had diffuse large B-cell lymphoma and adult T-cell leukemia/lymphoma.
  • Significant grade 3 to 4 toxicities were thrombocytopenia (n = 22), fatigue (n = 10), and peripheral neuropathy (n = 3).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma / drug therapy. Pyrazines / therapeutic use. Tumor Necrosis Factor-alpha / analysis
  • [MeSH-minor] Adult. Aged. Bortezomib. Cell Line, Tumor. Cell Survival / drug effects. Cytokines / blood. Doxorubicin / pharmacology. Female. Humans. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16606971.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501974
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Cytokines; 0 / Pyrazines; 0 / Tumor Necrosis Factor-alpha; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin
  •  go-up   go-down


23. Kästner F, Paulus W, Deckert M, Schlegel P, Evers S, Husstedt IW: [Primary CNS lymphoma in azathioprine therapy for autoimmune diseases: review of the literature and case report]. Nervenarzt; 2007 Apr;78(4):451-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary CNS lymphoma in azathioprine therapy for autoimmune diseases: review of the literature and case report].
  • We present a 31-year-old female patient with primary non-Hodgkin's lymphoma of the CNS after immunosuppressive therapy.
  • Stereotactic biopsy revealed immunochemical and histologic high-grade malignant B cell lymphoma.
  • The risk of primary CNS lymphoma under azathioprine treatment for an autoimmune disease with a possible congenital immunodeficiency is presented and the literature is reviewed.
  • [MeSH-major] Autoimmune Diseases / drug therapy. Azathioprine / adverse effects. Brain Neoplasms / chemically induced. Brain Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / chemically induced. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Colitis, Ulcerative / complications. Colitis, Ulcerative / drug therapy. Female. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Jan 27;347(8996):215-9 [8551879.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):72-7 [11781282.001]
  • [Cites] Lancet. 1994 May 21;343(8908):1249-52 [7910274.001]
  • [Cites] Gut. 2005 Aug;54(8):1121-5 [16009685.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1080-7 [11677199.001]
  • [Cites] Nervenarzt. 2004 Dec;75(12):1217-21 [15224176.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):199-201 [10563423.001]
  • [Cites] J Neurosurg. 1978 Dec;49(6):887-92 [366088.001]
  • [Cites] Neurology. 1988 Feb;38(2):258-61 [3340289.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Sep;2(9):731-43 [15354273.001]
  • [Cites] Curr Opin Gastroenterol. 2003 Jul;19(4):366-70 [15703578.001]
  • [Cites] Nervenarzt. 2001 Feb;72(2):136-42 [11256148.001]
  • [Cites] Acta Neuropathol. 2000 Jun;99(6):709-14 [10867808.001]
  • [Cites] P R Health Sci J. 2005 Sep;24(3):191-5 [16329682.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):203-8 [10563424.001]
  • [Cites] Ann Intern Med. 1989 Oct 15;111(8):641-9 [2802419.001]
  • [Cites] Am J Gastroenterol. 1999 Nov;94(11):3248-53 [10566724.001]
  • [Cites] Neurology. 1986 Jul;36(7):1011-2 [3714049.001]
  • [Cites] Ann Neurol. 2000 May;47(5):682-3 [10805346.001]
  • [Cites] J Nephrol. 2005 Sep-Oct;18(5):521-8 [16299677.001]
  • [Cites] Brain Pathol. 2001 Oct;11(4):440-51 [11556690.001]
  • [Cites] J Neurol Sci. 2000 Dec 1;181(1-2):1-12 [11099705.001]
  • [Cites] J Neurol. 1979 Jan 5;220(4):259-68 [90135.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Jul;16(7):1225-32 [12144571.001]
  • [Cites] Invest New Drugs. 2005 Dec;23(6):523-32 [16267626.001]
  • [Cites] Ann Rheum Dis. 1980 Oct;39(5):457-61 [7436577.001]
  • [Cites] Pathol Res Pract. 1998;194(7):473-86 [9728364.001]
  • [Cites] Am J Clin Oncol. 2005 Aug;28(4):427-8 [16062089.001]
  • [Cites] Transplantation. 2003 Sep 27;76(6):930-7 [14508356.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1504-10 [12237919.001]
  • [Cites] Scand J Gastroenterol Suppl. 2002;(236):48-53 [12408504.001]
  • [Cites] Am J Epidemiol. 2005 Nov 15;162(10):965-74 [16192343.001]
  • [Cites] Gut. 2000 Oct;47(4):514-9 [10986211.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Aug;15(8):1101-8 [11472312.001]
  • [Cites] Herpes. 2004 Jun;11 Suppl 2:120A-127A [15319099.001]
  • [Cites] Ann Rheum Dis. 1988 Dec;47(12):988-92 [3207388.001]
  • [Cites] Neurology. 2001 Jan 23;56(2):257-60 [11160967.001]
  • [Cites] Am J Hematol. 2002 Mar;69(3):171-8 [11891803.001]
  • [Cites] Wien Klin Wochenschr. 2005 Mar;117(5-6):229-33 [15875764.001]
  • [Cites] Ann Rheum Dis. 1984 Apr;43(2):128-31 [6712287.001]
  • [Cites] Am J Med. 1985 Jan 21;78(1A):44-9 [3970040.001]
  • [Cites] Environ Mol Mutagen. 1999;34(2-3):131-9 [10529737.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):91-2 [16078114.001]
  • [Cites] Mod Pathol. 1999 Feb;12(2):200-17 [10071343.001]
  • [Cites] Arthritis Rheum. 1972 Mar-Apr;15(2):183-6 [4554891.001]
  • [Cites] Leuk Lymphoma. 1997 Dec;28(1-2):187-93 [9498719.001]
  • (PMID = 17375274.001).
  • [ISSN] 0028-2804
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; MRK240IY2L / Azathioprine
  • [Number-of-references] 48
  •  go-up   go-down


24. Yang S, Jun M, Hong-Li Z, Jian-Min W, Chun W, Lu-Gui Q, Yong-Qiang Z, Jun Z, Jian H, Zhi-Xiang S: A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population. Int J Hematol; 2008 Sep;88(2):139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population.
  • The purpose of this study is to investigate the efficacy and safety of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma (MM), low-grade non-Hodgkin's lymphoma (NHL), and chronic lymphocytic leukemia (CLL).
  • From December 2005 to November 2006, the patients with MM, low-grade NHL, and CLL were enrolled in this study, male or female, aged > or = 18 years, transfusion-dependant, and receiving anti-neoplasia chemotherapy.
  • Hypertension (12.2%) is the most common adverse effect; however, all the adverse events were mild, categorized in NCI grade I or II.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. Female. Ferritins / blood. Humans. Iron / blood. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Lymphoma, Non-Hodgkin / complications. Male. Middle Aged. Multiple Myeloma / complications. Recombinant Proteins. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Anemia.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stem Cells. 1995 Jan;13(1):32-7 [7719246.001]
  • [Cites] Ann Oncol. 1993 Feb;4(2):161-7 [8448084.001]
  • [Cites] N Engl J Med. 1990 Jun 14;322(24):1693-9 [2342535.001]
  • [Cites] Br J Haematol. 1998 Jan;100(1):79-89 [9450795.001]
  • [Cites] J Am Soc Nephrol. 1994 Aug;5(2):177-85 [7993997.001]
  • [Cites] Cancer Prev Control. 1997 Aug;1(3):241-8 [9765749.001]
  • [Cites] Semin Oncol. 1992 Jun;19(3 Suppl 8):29-35 [1615337.001]
  • [Cites] Stem Cells. 1993 Sep;11(5):348-55 [8241947.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1109-15 [9834824.001]
  • [Cites] Hematol Oncol Clin North Am. 1994 Dec;8(6):1223-53 [7860446.001]
  • [Cites] Int J Hematol. 1992 Apr;55(2):197-203 [1511168.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2486-94 [12011126.001]
  • [Cites] Oncol Rep. 1998 Jan-Feb;5(1):81-6 [9458299.001]
  • [Cites] Nephrol Dial Transplant. 1999;14 Suppl 2:85-92 [10334673.001]
  • [Cites] Int J Oncol. 1993 Dec;3(6):1121-6 [21573482.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34 [10511589.001]
  • [Cites] Med Oncol. 1998 Aug;15 Suppl 1:S29-34 [9785334.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):23-6 [9671326.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2675-82 [8639883.001]
  • (PMID = 18629603.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / epoetin beta; 11096-26-7 / Erythropoietin; 9007-73-2 / Ferritins; E1UOL152H7 / Iron
  •  go-up   go-down


25. Ohga S, Nakamura K, Shioyama Y, Sasaki T, Urashima Y, Terashima H, Honda H: Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy. Radiat Med; 2005 May;23(3):156-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy.
  • PURPOSE: We evaluated the usefulness of radiotherapy plus THP-COP chemotherapy consisting of cyclophosphamide, vincristine, pirarubicin (tetrahydropyranyl adriamycin, THP), and prednisone for stage I and II non-Hodgkin's lymphoma (NHL).
  • The histological type was intermediate grade in 29, high in one, and unclassified in two.
  • Leukopenia of grade 3-4 was documented in 24 patients (75%) and thrombopenia of grade 3-4 in four (12.5%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15940061.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


26. Lohan DG, Alhajeri AN, Cronin CG, Roche CJ, Murphy JM: MR enterography of small-bowel lymphoma: potential for suggestion of histologic subtype and the presence of underlying celiac disease. AJR Am J Roentgenol; 2008 Feb;190(2):287-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR enterography of small-bowel lymphoma: potential for suggestion of histologic subtype and the presence of underlying celiac disease.
  • OBJECTIVE: The objective of our study was to evaluate the morphologic appearances of small-bowel lymphoma using MR enterography to identify key morphologic traits capable of providing an association between imaging manifestations and likely histologic diagnosis.
  • MATERIALS AND METHODS: Over a 54-month period, 10 patients with subsequently confirmed small-bowel lymphoma were imaged using a standardized MR enterography technique.
  • This patient group comprised 10 patients with non-Hodgkin's lymphoma (NHL) of various subtypes.
  • No cases of Hodgkin's lymphoma were encountered.
  • Luminal stricturing was encountered in cases of low-grade lymphoma, whereas mesenteric fat infiltration represented a characteristic of high-grade disease.
  • CONCLUSION: We describe the characteristics of small-bowel lymphoma on MR enterography, identifying a number of key features that may help the interpreting radiologist in suggesting the underlying histologic subtype and whether the presence of underlying celiac disease is likely.
  • [MeSH-major] Celiac Disease / diagnosis. Celiac Disease / etiology. Intestinal Neoplasms / complications. Intestinal Neoplasms / pathology. Intestine, Small / pathology. Lymphoma / complications. Lymphoma / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Reproducibility of Results. Sensitivity and Specificity


27. Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E, Chiesa C, Bombardieri E, Di Nicola M, Carlo-Stella C, Gianni AM: High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol; 2008 Nov 10;26(32):5175-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To develop high-dose myeloablative therapy for CD20(+) non-Hodgkin's lymphoma (NHL) as a safe and widely applicable regimen.
  • The only exclusion criteria were CNS lymphoma and Eastern Cooperative Oncology Group performance status of more than 3.
  • Infections occurred in 27% of patients (none had a severity grade greater than 3).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Ambulatory Care. Antigens, CD20 / analysis. Chemotherapy, Adjuvant. Cytogenetic Analysis. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Time Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Mar 1;27(7):1145-6; author reply 1146 [19171699.001]
  • [CommentIn] J Clin Oncol. 2008 Nov 10;26(32):5147-50 [18854559.001]
  • (PMID = 18854569.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / ibritumomab tiuxetan
  •  go-up   go-down


28. Raida L, Papajík T, Indrák K, Herman M, Paucek B, Zapletalová J: [Chemotherapy of BOVAPEC in the primary treatment of Hodgkin's lymphoma intermediate stages]. Vnitr Lek; 2007 Jan;53(1):31-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of BOVAPEC in the primary treatment of Hodgkin's lymphoma intermediate stages].
  • DESIGN: Chemotherapy of BOVAPEC is the modification of temporary intensified Stanford V protocol, an effective primary treatment of advanced Hodgkin's lymphoma (HL) in spite of limited toxicity.
  • RESULTS: During the treatment, a neutropenia of grade 3 and 4 was observed in 14 patients (23%) but without the development of any serious infectious complications.
  • The manifestation of early non-hematological toxicity did not overcome grade 2.58 patients (94%) achieved the complete remission of HL.
  • [MeSH-minor] Adult. Aged. Bleomycin / adverse effects. Bleomycin / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Male. Middle Aged. Prednisolone / adverse effects. Prednisolone / therapeutic use. Vinblastine / adverse effects. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vnitr Lek. 2007 Jan;53(1):7-8 [17472009.001]
  • (PMID = 17472013.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BOVAPEC protocol
  •  go-up   go-down


29. Laane E, Tani E, Björklund E, Elmberger G, Everaus H, Skoog L, Porwit-MacDonald A: Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma. Cytometry B Clin Cytom; 2005 Mar;64(1):34-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma.
  • BACKGROUND: Fine-needle aspiration (FNA) with immunophenotyping by immunocytochemistry (IC) on cytospins has recently received increased consideration in the diagnosis of lymphoma.
  • The aim of our study was to establish the diagnostic value of a four-color flow cytometric (FCM) panel, including cytoplasmic Bcl-2, in cytologic diagnosis of malignant non-Hodgkin's lymphoma (NHL) and reactive lymphoid hyperplasia (RH).
  • FCM gave correct immunologic diagnosis in 95% of low-grade B-cell NHLs, 78% of high-grade B-cell NHLs, and 53% of T-cell lymphomas.
  • [MeSH-major] Flow Cytometry / methods. Immunophenotyping / methods. Lymphoma, Non-Hodgkin / diagnosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Pseudolymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. B-Lymphocytes / chemistry. B-Lymphocytes / pathology. Biopsy, Fine-Needle. CD4-CD8 Ratio. Cell Proliferation. Child. Child, Preschool. Female. Humans. Immunoglobulin kappa-Chains / analysis. Immunoglobulin lambda-Chains / analysis. Lymphocyte Count. Lymphoma, T-Cell / blood. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Sensitivity and Specificity. T-Lymphocytes / chemistry. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15669024.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


30. Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, Müller C, Müller C, East German Study Group Hematology and Oncology (OSHO): Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol; 2006 Feb;132(2):105-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
  • PURPOSE: The purpose of this study was to compare the efficacy and toxicity of bendamustine, vincristine + prednisone (BOP) with a standard regimen of cyclophosphamide, vincristine + prednisone (COP) in patients with previously untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma.
  • METHODS: A total of 164 patients with follicular lymphoma (grade 1/2), mantle cell lymphoma or lymphoplasmacytic lymphoma (immunocytoma) was randomised to treatment with vincristine 2 mg (day 1) and prednisone 100 mg/m2 (days 1-5) + bendamustine 60 mg/m2 (days 1-5) or + cyclophosphamide 400 mg/m2 (days 1-5) for a total of eight 21-day cycles.
  • CONCLUSIONS: Bendamustine can efficaciously and safely replace cyclophosphamide, as used in standard COP therapy, for the treatment of patients with indolent NHL and mantle cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Bendamustine Hydrochloride. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Nitrogen Mustard Compounds / administration & dosage. Prednisone / administration & dosage. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1670-2 [3655864.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Anticancer Drugs. 1996 Jun;7(4):415-21 [8826610.001]
  • [Cites] Ann Intern Med. 1972 Feb;76(2):227-34 [5066691.001]
  • [Cites] Biochem Pharmacol. 2003 Sep 1;66(5):711-24 [12948851.001]
  • [Cites] Internist (Berl). 1997 Nov;38(11):1131-42 [9453969.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2445-9 [15621757.001]
  • [Cites] Semin Oncol. 1998 Aug;25(4):483-91 [9728598.001]
  • [Cites] Anticancer Drugs. 2001 Oct;12(9):725-9 [11593053.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Nov;128(11):603-9 [12458340.001]
  • (PMID = 16088404.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nitrogen Mustard Compounds; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 981Y8SX18M / Bendamustine Hydrochloride; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


31. Agarwal PA, Menon S, Smruti BK, Singhal BS: Primary central nervous system lymphoma: a profile of 26 cases from Western India. Neurol India; 2009 Nov-Dec;57(6):756-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: a profile of 26 cases from Western India.
  • BACKGROUND: Primary central nervous system (CNS) lymphoma (PCNSL) is a rare malignant non-Hodgkin's lymphoma and it accounts for 1% of all intracranial tumors.
  • AIMS: This study attempts to further delineate the clinical, radiological and pathological profile of PCNSL in India, to evaluate response to treatment and to assess usefulness of the International Extranodal Lymphoma Study Group (IELSG) score.
  • Pathological studies showed high grade diffuse large B-cell (DLBCL) histology in 96.2% of patients.
  • High grade DLBCL is the commonest histological subtype.
  • [MeSH-major] Central Nervous System Neoplasms. Lymphoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antiretroviral Therapy, Highly Active / methods. Enzyme-Linked Immunosorbent Assay / methods. Female. HIV Seropositivity / drug therapy. Humans. India / epidemiology. L-Lactate Dehydrogenase / blood. Magnetic Resonance Imaging / methods. Male. Mental Status Schedule. Middle Aged. Retrospective Studies. Treatment Outcome


32. Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA: Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network. J Clin Oncol; 2005 Mar 1;23(7):1500-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
  • PURPOSE: To evaluate the feasibility and efficacy of rituximab with short-duration chemotherapy in the first-line treatment of patients with follicular non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Patients with previously untreated stage II-IV follicular NHL, grade 1 or 2, were eligible for this multicenter phase II trial.
  • Five patients (6%) died from lymphoma; the overall actuarial survival at 3 years was 95%.
  • Grade 3/4 leukopenia occurred in 53% of patients, but only six patients (7%) had neutropenia or fever.
  • Grade 3/4 nonhematologic toxicities were uncommon.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / toxicity. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Follow-Up Studies. Humans. Injections, Intravenous. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / toxicity. Rituximab. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Vincristine / toxicity

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632411.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; COP protocol 2
  •  go-up   go-down


33. He YF, Li YH, Huang HQ, Xia ZJ, Sun XF, Lin TY, Lin XB, Yuan ZY, Li ZM, Wang FH, Wang SS, Jiang WQ: [Clinical analysis of 59 cases of primary gastric non-Hodgkin's lymphoma]. Ai Zheng; 2005 Apr;24(4):475-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 59 cases of primary gastric non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: Gastrointestinal tract is the most common extranodal involvement site of non-Hodgkin's lymphoma (NHL).
  • According to Working Formulation, most of them were in intermediate grade (46, 78.0%).
  • For those patients in intermediate grade (including immunoblastic cell lymphoma), there was no significant difference in the 5-year survival rate between the patients received chemotherapy plus surgery and the patients received chemotherapy alone (52.5% vs. 57.1%).
  • CONCLUSIONS: Chemotherapy-dominated modality is recommended for patients with PGNHL of intermediate or high grade.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820073.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


34. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol; 2007 Jan;18(1):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
  • BACKGROUND: Central nervous system (CNS) relapse is a devastating and usually fatal complication of aggressive lymphoma.
  • We analyzed the patients treated on protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) between 1990 and 2000, evaluated the rate and prognostic factors for CNS recurrence and developed a risk model trying to identify subsets of patients suitable for future prophylactic strategies.
  • The protocol asked for an intrathecal (i.th.) prophylaxis in patients with lymphoblastic lymphoma only (n=17), but overall 71 patients (71 of 1693=4.2%) received prophylaxis by decision of the treating physicians.
  • Elderly patients presenting with both an elevated LDH and lymphoma involvement in liver, bladder or adrenals had an up to 15-fold risk of spread of the disease to the CNS.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018708.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone
  •  go-up   go-down


35. Pasqualotto AC, Rosa DD, Medeiros LR, Severo LC: Candidaemia and cancer: patients are not all the same. BMC Infect Dis; 2006;6:50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of solid cancers were non-metastatic (71.9%).
  • Major diagnoses in patients with haematological neoplasia were acute leukaemia (n = 13), high grade non-Hodgkin lymphoma (n = 5) and Hodgkin's disease (n = 1).
  • Non-Candida albicans species caused 57.8% of the episodes of candidaemia in patients with cancer, mainly in patients with haematological malignancies (p = 0.034).
  • We then compared 2 groups of adult patients with candidaemia.
  • The first was composed of non-neutropenic patients with solid tumours, and the second group included patients without cancer.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antifungal Agents / therapeutic use. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Male. Middle Aged. Odds Ratio. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Support Care Cancer. 1999 Nov;7(6):428-31 [10541986.001]
  • [Cites] J Infect. 2006 Mar;52(3):216-22 [15936825.001]
  • [Cites] Clin Infect Dis. 2001 Nov 15;33(10):1676-81 [11568858.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] J Antimicrob Chemother. 2002 Feb;49 Suppl 1:3-6 [11801574.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):730-51 [11850858.001]
  • [Cites] Am J Med. 2002 Apr 1;112(5):380-5 [11904112.001]
  • [Cites] J Infect. 2003 Apr;46(3):155-60 [12643863.001]
  • [Cites] Support Care Cancer. 2004 Jul;12(7):511-6 [14986077.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):411-9 [6581852.001]
  • [Cites] Am J Med. 1984 Oct 30;77(4D):13-9 [6093529.001]
  • [Cites] Am J Med. 1984 Oct 30;77(4D):20-7 [6093530.001]
  • [Cites] J Clin Microbiol. 1988 Mar;26(3):429-32 [3356785.001]
  • [Cites] Rev Infect Dis. 1991 Mar-Apr;13(2):211-5 [2041951.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1992 Feb;11(2):99-109 [1396746.001]
  • [Cites] Scand J Infect Dis. 1997;29(3):301-4 [9255894.001]
  • [Cites] Acta Oncol. 1997;36(6):643-9 [9408157.001]
  • [Cites] Mycopathologia. 1998;141(2):65-8 [9750336.001]
  • [Cites] Clin Infect Dis. 1999 May;28(5):1071-9 [10452637.001]
  • [Cites] Rev Inst Med Trop Sao Paulo. 2004 Sep-Oct;46(5):239-41 [15517023.001]
  • [Cites] J Hosp Infect. 2005 Jun;60(2):129-34 [15866011.001]
  • [Cites] J Infect. 2005 Jun;50(5):443-9 [15907554.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):569-82 [15916679.001]
  • [Cites] Mycopathologia. 2005 Sep;160(2):111-6 [16170605.001]
  • [Cites] J Infect. 2005 Oct;51(3):260-1 [15982743.001]
  • [Cites] Scand J Infect Dis. 2001;33(5):367-74 [11440223.001]
  • (PMID = 16542444.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Other-IDs] NLM/ PMC1431538
  •  go-up   go-down


36. Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS: Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol; 2009 Mar;27(1):11-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age was 71, and the majority of enrolled patients had non-Hodgkin's lymphoma (12/17).
  • Sixteen patients were evaluable, and one patient with mantle cell lymphoma achieved an unconfirmed complete response after five cycles of therapy for an overall response rate of 6%.
  • Haematologic toxicities were the most commonly reported events in this heavily pre-treated population, and comprised the majority of grade 3 and 4 toxicities.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1383-91 [9737686.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1687-92 [16130126.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):521-9 [16396776.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Med Oncol. 2006;23(2):263-72 [16720927.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2465-71 [16651646.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2456-64 [16651647.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2624-9 [16688776.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1105-8 [16870552.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):174-83 [17010047.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):796-9 [10555748.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1014-22 [10648417.001]
  • [Cites] Br J Haematol. 2001 Mar;112(3):783-6 [11260084.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:17-21 [11331436.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:22-8 [11331437.001]
  • [Cites] Blood. 2001 Aug 1;98(3):805-13 [11468182.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1835-7 [12200700.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3658-68 [12473574.001]
  • [Cites] Leukemia. 2003 Jan;17(1):271-2 [12529694.001]
  • [Cites] Hum Exp Toxicol. 2002 Dec;21(12):675-80 [12540038.001]
  • [Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1028-34 [12676792.001]
  • [Cites] J Nutr Biochem. 2003 Jul;14(7):416-20 [12915223.001]
  • [Cites] Br J Haematol. 2004 May;125(4):470-6 [15142117.001]
  • [Cites] Anal Biochem. 1969 Mar;27(3):502-22 [4388022.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):194-205 [8270977.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1969s-1975s [8137322.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Blood. 1997 Jul 15;90(2):562-70 [9226155.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1789-96 [9392620.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1055-60 [9734658.001]
  • [Cites] Blood. 1999 Jan 1;93(1):268-77 [9864170.001]
  • (PMID = 18668698.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA087718-09; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA087718-09; United States / NCI NIH HHS / CA / CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; GAN16C9B8O / Glutathione; PQ6CK8PD0R / Ascorbic Acid; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ NIHMS212975; NLM/ PMC2897137
  •  go-up   go-down


37. Bilsel Y, Balik E, Yamaner S, Bugra D: Clinical and therapeutic considerations of rectal lymphoma: a case report and literature review. World J Gastroenterol; 2005 Jan 21;11(3):460-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and therapeutic considerations of rectal lymphoma: a case report and literature review.
  • Primary rectal lymphoma is a rare presentation of gastrointestinal lymphomas.
  • Although surgical resection is often technically feasible, optimal therapy for colorectal lymphoma has not yet been identified.
  • We report a case of primary rectal lymphoma (non-Hodgkin's large cell lymphoma of type B) with high-grade features that disappeared completely after chemo-radiotherapy.
  • This case underlines that primary treatment with systemic chemotherapy and involved-field radiotherapy can be successful for rectal lymphoma, with surgery reserved for complications and chemotherapy failures.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637770.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4205364
  •  go-up   go-down


38. Todisco M: Relapse of high-grade non-Hodgkin's lymphoma after autologous stem cell transplantation: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, melatonin, retinoids, and ACTH. Am J Ther; 2006 Nov-Dec;13(6):556-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of high-grade non-Hodgkin's lymphoma after autologous stem cell transplantation: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, melatonin, retinoids, and ACTH.
  • Patients with relapse of high-grade non-Hodgkin lymphoma (NHL) after autologous stem cell transplantation (auto-SCT) generally have a poor prognosis.
  • With a combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH, we already reported 100% global response in 8 patients with relapse of low-grade NHL after single or combined chemotherapy and a therapy-free period of > or = 6 months.
  • This provided the rationale to evaluate the same pharmacological association in a patient with relapse of high-grade NHL after auto-SCT performed 2 years before.
  • Our result and severe toxicities associated with conventional salvage treatments suggest in a relapse of high-grade NHL after auto-SCT, further clinical trials using the pharmacological association we employed in this case.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Stem Cell Transplantation
  • [MeSH-minor] Adrenocorticotropic Hormone / administration & dosage. Adult. Bromocriptine / administration & dosage. Cyclophosphamide / administration & dosage. Humans. Male. Melatonin / administration & dosage. Recurrence. Retinoids / administration & dosage. Somatostatin / administration & dosage. Time Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MELATONIN .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122540.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoids; 3A64E3G5ZO / Bromocriptine; 51110-01-1 / Somatostatin; 8N3DW7272P / Cyclophosphamide; 9002-60-2 / Adrenocorticotropic Hormone; JL5DK93RCL / Melatonin
  •  go-up   go-down


39. Zhu J, Wang WY, Jiang M, Yang Y, Hou M: [Correlation between VEGF expression and clinical characteristic of patient with non-Hodgkin's lymphoma: an initial study]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May;39(3):418-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between VEGF expression and clinical characteristic of patient with non-Hodgkin's lymphoma: an initial study].
  • OBJECTIVE: To study whether VEGF expression is associated with clinical characteristics such as gender, age, aggressive, stage, B-symptoms and complete remission (CR) rate of patients with non-Hodgkin's lymphoma.
  • RESULTS: Comparing VEGF positive rates grouped by sexuality, age, aggressive grade or stage, the results suggested no significant correlation between them.
  • CONCLUSIONS: Expression of VEGF is associated with B-symptoms and poor response to chemotherapy in patients with non-Hodgkin's lymphoma, there was not any relationship to have been found between VEGF expression and sexuality, age, aggressive grade, stage.
  • [MeSH-major] Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575329.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


40. Funk A, Hensley F, Krempien R, Neuhof D, Van Kampen M, Treiber M, Roeder F, Timke C, Herfarth K, Helmbold P, Debus J, Bischof M: Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma. Eur J Dermatol; 2008 May-Jun;18(3):308-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma.
  • Our aim was to analyze the effectiveness of palliative total skin electron beam therapy (TSEBT) in the management of advanced cutaneous T-cell non-Hodgkin's lymphoma (CTCL).
  • All patients suffered from lymphoma-associated symptoms.
  • Lymphoma associated symptoms were improved in 16 patients (89%).
  • Treatment related acute effects (grade 1 or 2) were observed in all patients during radiation therapy.
  • Transient grade 3 epitheliolyses developed in five patients (28%), late skin effects (grade 1 and 2) in 16 patients (89%), and hypohidrosis was seen in six patients (33%).
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / radiotherapy. Mycosis Fungoides / radiotherapy. Palliative Care / methods. Radiotherapy, High-Energy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Electrons / adverse effects. Electrons / therapeutic use. Female. Humans. Kaplan-Meier Estimate. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Large-Cell, Anaplastic / radiotherapy. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Sezary Syndrome / pathology. Sezary Syndrome / radiotherapy. Survival Rate. Treatment Outcome. Whole-Body Irradiation / adverse effects. Whole-Body Irradiation / methods


41. Hashemi-Bahremani M, Parwaresch MR, Tabrizchi H, Gupta RK, Raffii MR: Lymphomas in Iran. Arch Iran Med; 2007 Jul;10(3):343-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the histochemical methods, the immunohistochemical markers were used to examine the biopsied specimens of 434 patients with non-Hodgkin's and Hodgkin's lymphomas.
  • RESULTS: Out of the 385 cases that were diagnosed as lymphoma, 277 had non-Hodgkin's and 108 had Hodgkin's lymphomas.
  • Sixty-four point five percent of those with non-Hodgkin's lymphoma had the B type disease; 7.5% had the T-type; and the remaining 28% had Hodgkin's lymphoma.
  • In the present study, most (48%) patients with Hodgkin's lymphoma had mixed cellularity whereas in western countries the most common type is reported to be nodular sclerosis (69.4%).
  • CONCLUSION: The comparison made between the findings of this study and those of western countries indicates that high-grade non-Hodgkin's lymphomas are more prevalent in Iran.
  • [MeSH-major] Hodgkin Disease / classification. Hodgkin Disease / pathology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Europe / epidemiology. Humans. Incidence. Infant. Iran / epidemiology. Middle Aged. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17604472.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


42. Sewak S, Sorich J, O'Leary J: Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen. Anticancer Drugs; 2006 Jun;17(5):571-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All DLTs for both formulations were grade 4 hematologic toxicities (neutropenia and/or thrombocytopenia), while non-hematologic toxicities were relatively mild (including gastrointestinal toxicities and fatigue).
  • One patient each with non-Hodgkin's lymphoma and cancer of unknown primary had a PR.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702815.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16081-23; United States / NHLBI NIH HHS / HL / HL 07151; United States / NCRR NIH HHS / RR / MO1 RR 00096; United States / NCI NIH HHS / CA / P01 CA 50529; United States / NCI NIH HHS / CA / P03 CA 16087; United States / NCI NIH HHS / CA / R01 CA 54484; United States / NCI NIH HHS / CA / R01 CA 56129; United States / NHLBI NIH HHS / HL / T32 HL 07151
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5MB77ICE2Q / 9-aminocamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


43. Brugières L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A: Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol; 2009 Feb 20;27(6):897-903
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group.
  • PURPOSE: To compare the efficacy and safety of two methotrexate doses and administration schedules in children with anaplastic large-cell lymphoma (ALCL).
  • PATIENTS AND METHODS: This randomized trial for children with ALCL was based on the Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Muenster 90 (NHL-BFM90) study protocol and compared six courses of methotrexate 1 g/m2 over 24 hours and an intrathecal injection (IT) followed by folinic acid rescue at 42 hours (MTX1 arm) with six courses of methotrexate 3 g/m2 over 3 hours followed by folinic acid rescue at 24 hours without IT (MTX3 arm).
  • This trial involved most European pediatric/lymphoma study groups and a Japanese group.
  • Toxicity was assessed after 2,050 courses and included grade 4 hematologic toxicity after 79% and 64% of MTX1 and MTX3 courses, respectively (P < .0001); infection after 50% and 32% of courses, respectively (P < .0001); and grade 3 to 4 stomatitis after 21% and 6% of courses, respectively (P < .0001).
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Methotrexate / administration & dosage
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infant. Injections, Spinal. Male. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


44. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L: Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol; 2005 May;52(5):847-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary cutaneous B-cell lymphoma with rituximab.
  • Intravenous administration of rituximab has been used for the treatment of patients with low-, intermediate-, and high-grade B-cell non-Hodgkin's lymphomas and is a registered treatment modality for this indication.
  • Treatment of primary cutaneous B-cell lymphoma (CBCL) with intralesionally or systemically administered rituximab has been described only in a few cases.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / analysis. Female. Humans. Injections, Intralesional. Injections, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Rituximab

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858476.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


45. Horsman JM, Thomas J, Hough R, Hancock BW: Primary bone lymphoma: a retrospective analysis. Int J Oncol; 2006 Jun;28(6):1571-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone lymphoma: a retrospective analysis.
  • The aim of this study was to retrospectively define those patients with unequivocal primary bone lymphoma presenting to the Sheffield Lymphoma Group and document patient and tumour characteristics and management strategies, and correlate these with survival.
  • Thirty-seven patients were documented from a total of 3148 cases of non-Hodgkin's lymphoma seen over 34 years.
  • Grade 2 and diffuse large B cell lymphoma comprised the majority of histologies (78.7% and 70.3%, respectively).
  • Bone lymphoma has a better survival than other extranodal lymphomas.
  • [MeSH-major] Bone Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell / therapy. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Retrospective Studies. Survival Analysis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685458.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


46. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, Welker DA: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol; 2005 Feb 20;23(6):1103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
  • PURPOSE: Patients with newly diagnosed, advanced-stage, follicular grade 1 non-Hodgkin's lymphoma (NHL) are often asymptomatic and can be observed without immediate chemotherapy.
  • PATIENTS AND METHODS: Eligible patients had untreated follicular grade 1 NHL, and measurable stage III/IV disease.
  • CONCLUSION: Rituximab can be safely administered to patients with advanced-stage follicular grade 1 NHL with efficacy and minimal toxicity.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Disease Progression. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Neutropenia / chemically induced. Rituximab. Survival Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 20;23(6):1056-8 [15657408.001]
  • (PMID = 15657404.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


47. Takamatsu Y, Suzumiya J, Ogata K, Katayose K, Sasaki H, Ishitsuka K, Kimura N, Tamura K: Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. J Clin Exp Hematop; 2009 Nov;49(2):69-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study.
  • Cladribine is approved to be used in 24-hour continuous infusion for the treatment of low-grade lymphoma by the Ministry of Health, Labor and Welfare in Japan.
  • The safety and anti-tumor activity of short infusion of cladribine was shown in hairy cell leukemia, chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma in Europe.
  • We therefore underwent a pilot study to confirm the safety and efficacy of cladribine given by 2-hour infusion for Japanese patients with relapsed or refractory indolent B-cell lymphoma.
  • Grade 3 or 4 neutropenia and lymphocytopenia occurred in 43% and 71% of patients, respectively, but there was no febrile neutropenia or opportunistic infection associated with cladribine treatment.
  • No other adverse events greater than grade 3 were encountered.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cladribine / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Ambulatory Care / methods. Asian Continental Ancestry Group. Female. Humans. Infusions, Intravenous. Japan. Male. Middle Aged. Pilot Projects. Recurrence. Retrospective Studies

  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907111.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


48. Aksoy S, Harputluoglu H, Kilickap S, Dincer M, Dizdar O, Akdogan B, Ozen H, Erman M, Celik I: Erectile dysfunction in successfully treated lymphoma patients. Support Care Cancer; 2008 Mar;16(3):291-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erectile dysfunction in successfully treated lymphoma patients.
  • BACKGROUND: Information on male potency in lymphoma survivors is insufficient.
  • In this study, we assessed male sexual function and serum gonadotropins in successfully treated lymphoma patients.
  • MATERIALS AND METHODS: Fifty-nine patients treated for Hodgkin's lymphoma (HL) or non-HL (NHL) with chemotherapy +/- radiotherapy were included in the study.
  • Presence of ED and its grade were not different between HL and NHL patients.
  • Clinicians should be aware of this problem in lymphoma survivors and offer these patients adequate treatment options.
  • [MeSH-major] Erectile Dysfunction / epidemiology. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Chi-Square Distribution. Combined Modality Therapy. Gonadotropins / blood. Humans. Male. Middle Aged. Risk Factors. Statistics, Nonparametric. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Feb;13(2):333 [11886015.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):173-80 [15023435.001]
  • [Cites] Eur Urol. 1993;23(1):172-6 [8477777.001]
  • [Cites] Urology. 2002 Jun;59(6):803-10 [12031357.001]
  • [Cites] J Clin Oncol. 1986 May;4(5):805-14 [3486256.001]
  • [Cites] Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Sep;14(3):453-71 [11097786.001]
  • [Cites] Fertil Steril. 1985 Jun;43(6):927-30 [3922808.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2253-4 [15169819.001]
  • [Cites] Eur J Cancer. 1991;27(11):1389-92 [1835853.001]
  • [Cites] JAMA. 1981 Apr 3;245(13):1323-8 [7206131.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):979-88 [8487061.001]
  • [Cites] J Assoc Physicians India. 1994 Aug;42(8):604-5 [7868551.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1307-11 [11697845.001]
  • [Cites] Urology. 1997 Jun;49(6):822-30 [9187685.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):801-7 [10360658.001]
  • [Cites] Med Pediatr Oncol. 2000 Jul;35(1):52-63 [10881008.001]
  • [Cites] Int J Impot Res. 2004 Oct;16 Suppl 2:S26-39 [15496854.001]
  • [Cites] Eur Urol. 2005 Jan;47(1):80-5; discussion 85-6 [15582253.001]
  • [Cites] J Urol. 1994 Jan;151(1):54-61 [8254833.001]
  • (PMID = 17661093.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gonadotropins
  •  go-up   go-down


49. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, Van Hoof A, Tilly H, Gaulard P, Coiffier B, Gisselbrecht C, Brousse N, Reyes F, Hermine O, Groupe d'Etude des Lymphomes de l'Adulte Programs: Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol; 2006 Feb 20;24(6):953-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
  • PURPOSE: Epidemiologic studies show an association between hepatitis C virus (HCV) and B-cell non-Hodgkin's lymphoma (NHL).
  • Treatment and outcome of patients with diffuse large-cell lymphoma (DLCL) and HCV infection are still a matter of debate.
  • RESULTS: Histologic types of HCV-positive DLCL were more frequently transformed from low-grade lymphoma than DLCL in HCV-negative patients (32% v 6%, P = .02).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatitis C / complications. Hepatitis C Antigens / blood. Liver / drug effects. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Aged. Antiviral Agents / therapeutic use. Disease-Free Survival. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Seroepidemiologic Studies. Severity of Illness Index. Spleen / pathology. Spleen / virology. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Jul 20;24(21):3513; author reply 3513-4 [16849775.001]
  • (PMID = 16418500.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis C Antigens
  •  go-up   go-down


50. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med; 2010 Nov 4;363(19):1812-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30.
  • METHODS: In this phase 1, open-label, multicenter dose-escalation study, we administered brentuximab vedotin (at a dose of 0.1 to 3.6 mg per kilogram of body weight) every 3 weeks to 45 patients with relapsed or refractory CD30-positive hematologic cancers, primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma.
  • Treatment was associated primarily with grade 1 or 2 (mild-to-moderate) toxic effects. (Funded by Seattle Genetics; ClinicalTrials.gov number, NCT00430846.).
  • [MeSH-major] Hodgkin Disease / drug therapy. Immunoconjugates / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged, 80 and over. Antigens, CD30. Chemokine CCL17 / blood. Dose-Response Relationship, Drug. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Peripheral Nervous System Diseases / chemically induced. Recurrence. Remission Induction. Young Adult


51. Cikota BM, Tukić LJ, Tarabar OT, Magić ZM: Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma. J Exp Clin Cancer Res; 2007 Dec;26(4):535-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma.
  • The study included 40 B-NHL patients--13/40 patients with high- (HG) and 27/40 with low-grade (LG) lymphoma.
  • [MeSH-major] Genes, p53. Genes, ras. Lymphoma, B-Cell / genetics. Mutation. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365550.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


52. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2005 Feb 1;23(4):667-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • PURPOSE: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies.
  • RESULTS: Sixty patients with a median number of prior therapies of 3.5 (range, one to 12 therapies) were enrolled; 33 patients were in arm A and 27 were in arm B, including 12 diffuse large B-cell lymphomas, five follicular lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal zone lymphoma.
  • In arm B, four of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirmed, one diffuse large B-cell lymphoma patient had a PR, and one WM patient had a PR) for an ORR of 19% (95% CI, 5% to 42%).
  • Grade 3 toxicity included thrombocytopenia (47%), gastrointestinal (20%), fatigue (13%), neutropenia (10%), and peripheral neuropathy (5%).
  • Grade 4 toxicity occurred in nine patients (15%), and three deaths from progression of disease occurred within 30 days of withdrawal from study.
  • CONCLUSION: Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma, B-Cell / drug therapy. Protease Inhibitors / therapeutic use. Pyrazines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bortezomib. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 1;23(4):657-8 [15613690.001]
  • (PMID = 15613697.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


53. Jin Y, Li YC, Su ZL, Tang LY, Feng ZY, Guo SZ: [Protein expressions of Fas and FasL in B-cell lymphoma and their significances]. Ai Zheng; 2005 Mar;24(3):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Protein expressions of Fas and FasL in B-cell lymphoma and their significances].
  • This study was designed to detect protein expressions of Fas and FasL in B-cell non-Hodgkin's lymphoma (B-NHL) and benign lymphoid tissue, and to provide new markers for diagnosis of lymphoma.
  • Positive rates of Fas and FasL were higher in diffuse large B-cell lymphoma (DLBL) than in follicular lymphoma (FL), and small cell lymphoma (SLL) (87.2% vs. 64.5%, and 31.8%, P<0.05u 89.7% vs. 67.7%, and 27.3%, P<0.05).
  • CONCLUSIONS: The expressions of Fas and FasL are not useful for distinguishing benign lymphoid tissue from lymphoma tissue, while their locational characteristics are valuable for differential diagnosis.
  • The expressions of Fas and FasL are considered valuable in evaluating the malignant grade of B-NHL.
  • [MeSH-major] Antigens, CD95 / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Follicular / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Membrane Glycoproteins / metabolism. Tumor Necrosis Factors / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Membrane / metabolism. Child. Child, Preschool. Cytoplasm / metabolism. Diagnosis, Differential. Fas Ligand Protein. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell. Lymphadenitis / metabolism. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757536.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Tumor Necrosis Factors
  •  go-up   go-down


54. Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, Ungari M, Ruggeri G, Rossi G: Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma; 2006 Jun;47(6):1013-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study analysed all cases of unexplained delayed-onset peripheral blood cytopenia of WHO grade II - IV occurring in an unselected series of patients treated with rituximab in order to evaluate its prevalence and clinical significance.
  • Seventy-seven courses of rituximab (corresponding to 317 rituximab infusions) given to 72 consecutive patients affected by non-Hodgkin's Lymphoma and treated at a single Center with rituximab, alone (nine cases), associated with chemotherapy (50) or with chemotherapy and autologous stem cell transplantation (18) were evaluated.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Leukopenia / chemically induced. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Risk Factors. Rituximab. Time Factors

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Jun;47(6):965-6 [16840184.001]
  • (PMID = 16840190.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


55. Tulpule A, Espina BM, Berman N, Buchanan LH, Smith DL, Sherrod A, Dharmapala D, Gee C, Boswell WD, Nathwani BN, Welles L, Levine AM: Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma; 2006 Jul;7(1):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
  • BACKGROUND: The toxicity and efficacy of nonpegylated liposomal doxorubicin (TLC D-99) when substituted for conventional doxorubicin in the CHOP (doxorubicin/cyclophosphamide/vincristine/prednisone) regimen were evaluated in the treatment of newly diagnosed patients with aggressive non-Hodgkin's lymphoma.
  • Reversible grade 3/4 neutropenia was the most common toxicity (95.8%).
  • Most nonhematologic side effects were grade 1/2 in severity.
  • Immunohistochemistry for MDR-1-related p-glycoprotein was assessed in lymphoma tissues from 27 patients.
  • Of the 27 lymphoma tissues studied, 8 (30%) were MDR-1 positive at diagnosis.
  • CONCLUSION: Nonpegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, and prednisone is an active regimen for patients with newly diagnosed, aggressive non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Prednisone / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Remission Induction. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879771.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


56. Chakraborty J, Paul PC, Sarkar R, Rao RN: Primary non-Hodgkin's lymphoma of breast: a case report. Indian J Pathol Microbiol; 2007 Apr;50(2):315-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of breast: a case report.
  • Primary breast lymphoma is a relatively uncommon neoplasm, majority being of B-cell origin.
  • Though cytologic diagnosis of breast lymphoma is an easy procedure and provides guidance for appropriate pre-operative management, it is often impossible to differentiate a low grade lymphoma from reactive proliferation.
  • Lymphoepithelial lesions were identified histologically, and the majority of the cell population were confirmed as lymphoma cells of B-cell origin on immunohistochemistry.
  • This case highlights the limitations of cytology and the importance of histological examination supported by immunohistochemistry for making a diagnosis of low grade primary breast lymphoma.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Adult. Antigens, CD20 / metabolism. Antigens, CD79 / metabolism. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883054.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; 0 / CD79A protein, human
  •  go-up   go-down


57. Fu P, van Heeckeren WJ, Wadhwa PD, Bajor DJ, Creger RJ, Xu Z, Cooper BW, Laughlin MJ, Gerson SL, Koç ON, Lazarus HM: Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation. Contemp Clin Trials; 2008 Mar;29(2):157-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation.
  • We developed a modified statistical model based on histologic grade and other variables to describe the time-dependent outcome for autologous stem cell transplant (autotransplant) performed for non-Hodgkin's lymphoma (NHL) based on histologic grade and other variables.
  • Cox proportional hazards model analysis showed that proportionality did not hold for lymphoma grade, indicating that the relationship between the grade and disease-free survival differed over time.
  • The time-dependent effect of lymphoma grade on disease-free survival suggests the need for early (within first year) incorporation of novel therapeutic approaches in management of patients with indolent NHL undergoing autotransplant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Models, Statistical. Proportional Hazards Models. Time. Transplantation, Autologous. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707140.001).
  • [ISSN] 1551-7144
  • [Journal-full-title] Contemporary clinical trials
  • [ISO-abbreviation] Contemp Clin Trials
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


58. Shukla D, Arora A, Hadi KM, Kumar M, Baddela S, Kim R: Combined central retinal artery and vein occlusion secondary to systemic non-Hodgkin's lymphoma. Indian J Ophthalmol; 2006 Sep;54(3):204-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined central retinal artery and vein occlusion secondary to systemic non-Hodgkin's lymphoma.
  • We report a rare case of low-grade systemic B-cell non-Hodgkin's lymphoma (NHL) causing central retinal artery and vein occlusion, which was the only manifestation of disease recurrence.
  • [MeSH-major] Lymphoma, B-Cell / complications. Retinal Artery Occlusion / etiology. Retinal Vein Occlusion / etiology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Fluorescein Angiography. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921223.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


59. Hashino S, Morita L, Takahata M, Onozawa M, Nakagawa M, Kawamura T, Fujisawa F, Kahata K, Izumiyama K, Yonezumi M, Chiba K, Kondo T, Asaka M: Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol; 2008 Jan;87(1):91-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Underlying diseases included acute leukemia (n = 16), non-Hodgkin's lymphoma (n = 11), myelodysplastic syndrome (n = 6), and others (n = 11) in the MCFG group and acute leukemia (n = 18), chronic myelogenous leukemia (n = 6), and others (n = 5) in the FLCZ group.
  • Although one patient in the MCFG group required the discontinuation of MCFG due to allergic skin eruption (grade 2), none of the other patients in either group required dose reduction due to adverse effects.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluconazole / therapeutic use. Humans. Lipopeptides. Male. Middle Aged. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2004 Sep;10(9):645-52 [15319776.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):40-6 [11918531.001]
  • [Cites] J Infect Dis. 1995 Jun;171(6):1545-52 [7769290.001]
  • [Cites] Lancet. 2007 May 5;369(9572):1519-27 [17482982.001]
  • [Cites] Lancet. 2003 Oct 4;362(9390):1142-51 [14550704.001]
  • [Cites] Blood. 2003 Aug 1;102(3):827-33 [12689933.001]
  • [Cites] N Engl J Med. 1992 Mar 26;326(13):845-51 [1542320.001]
  • [Cites] Bone Marrow Transplant. 2006 Nov;38(10):693-8 [16980989.001]
  • [Cites] Intern Med. 2006;45(5):259-64 [16595990.001]
  • [Cites] Ann Intern Med. 2003 May 6;138(9):705-13 [12729424.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jul;13(7):771-7 [17580255.001]
  • [Cites] Clin Infect Dis. 2004 Nov 15;39(10):1407-16 [15546073.001]
  • [Cites] Antimicrob Agents Chemother. 1993 Sep;37(9):1847-9 [8239594.001]
  • [Cites] Expert Rev Anti Infect Ther. 2006 Jun;4(3):457-68 [16771622.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4358-66 [12393425.001]
  • [Cites] N Engl J Med. 1991 Oct 31;325(18):1274-7 [1669837.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2055-61 [10979947.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1527-33 [14525770.001]
  • [Cites] J Infect Dis. 2004 Aug 1;190(3):641-9 [15243943.001]
  • (PMID = 18224421.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Lipopeptides; 0 / Lipoproteins; 8VZV102JFY / Fluconazole; R10H71BSWG / micafungin
  •  go-up   go-down


60. Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, Pruneri G, Radice D, Pinto A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G: Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol; 2010 May 1;28(13):2233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No patients developed transformation to high-grade non-Hodgkin's lymphoma nor myelodysplasia.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cladribine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Genotype. Humans. Immunophenotyping. Injections, Subcutaneous. Italy. Kaplan-Meier Estimate. Male. Membrane Transport Proteins / genetics. Membrane Transport Proteins / metabolism. Middle Aged. Patient Selection. Phenotype. Prospective Studies. Rituximab. Time Factors. Treatment Outcome. ZAP-70 Protein-Tyrosine Kinase / genetics. ZAP-70 Protein-Tyrosine Kinase / metabolism


61. Taylor AL, Bowles KM, Callaghan CJ, Wimperis JZ, Grant JW, Marcus RE, Bradley JA: Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation; 2006 Aug 15;82(3):375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In view of the similarities between monomorphic PTLD and non-Hodgkin's lymphoma in the general population, our policy is to treat monomorphic PTLD with anthracycline-based chemotherapy as first-line treatment.
  • RESULTS: Of the 18 patients with PTLD, 13 had high-grade malignant lymphoma on diagnostic biopsy and received anthracycline-based chemotherapy and reduction in immunosuppression as first-line therapy.
  • Four (22%) patients had polymorphic PTLD on diagnostic biopsy (of which two were re-classified as monomorphic) and one had a low-grade malignant lymphoma.
  • [MeSH-major] Anthracyclines / therapeutic use. Kidney Transplantation. Lymphoma / drug therapy. Lymphoma / pathology. Lymphoproliferative Disorders / drug therapy. Lymphoproliferative Disorders / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906036.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


62. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF: Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol; 2006 May;17 Suppl 4:iv25-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
  • We have treated 75 transplant-eligible patients with relapsed or refractory lymphoma using an outpatient-based fractionated regimen of ifosfamide, carboplatin and etoposide (ICE) for both salvage and stem cell mobilisation.
  • Patients included DLBC (n = 33), follicular (n = 23), NK/T-cell (n = 3), mantle cell (n = 3) and Hodgkin's lymphoma (n = 13).
  • Most patients with indolent lymphoma also received rituximab.
  • Non-haematological toxicities included grade 1/2 CNS toxicity in four patients, cardiac toxicity in two, reversible renal impairment and haematuria in one each.
  • These data confirm the efficacy and tolerability of outpatient fractionated ICE as both a salvage and mobilisation regimen in relapsed/refractory lymphoma.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702181.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


63. Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M: Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica; 2007 Jan;92(1):35-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Response to pre-transplant salvage chemotherapy remains the most important prognostic factor for outcome in refractory or relapsed Hodgkin's lymphoma.
  • DESIGN AND METHODS: Ninety-one patients with refractory or relapsed Hodgkin's lymphoma were treated prospectively with a salvage regimen consisting of ifosfamide 2000 mg/m2 on days 1 to 4, gemcitabine 800 mg/m2 on days 1 and 4, vinorelbine 20 mg/m2 on day 1, and prednisolone 100 mg on days 1 to 4 (IGEV).
  • No grade 4 non-hematologic toxicity was observed, except for one episode of mucositis.
  • INTERPRETATION AND CONCLUSIONS: The high response rate, in particular the complete remission rate, the low toxicity profile, and the very high mobilizing potential of the IGEV regimen strongly suggest that patients with relapsed/refractory Hodgkin's lymphoma may benefit from the use of this salvage induction regimen.
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / biosynthesis. Female. Humans. Male. Middle Aged. Recurrence. Stem Cell Transplantation. Treatment Outcome


64. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A: Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Mar;47(3):481-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
  • Patients included in the present study had recurrent or refractory aggressive non-Hodgkin's lymphoma (NHL), had received two to three prior treatment regimens, and had good performance status and marrow reserve.
  • After the first course of therapy, grade 4 neutropenia developed in all 20 patients.
  • The mean +/- SD duration of grade 4 neutropenia was 3.8 +/- 1.7 days.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Neutrophils / drug effects. Paclitaxel / administration & dosage. Topotecan / administration & dosage
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Filgrastim. Humans. Injections, Intravenous. Injections, Subcutaneous. Leukocyte Count. Male. Middle Aged. Recombinant Proteins. Recurrence. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396772.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


65. Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW, United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519): Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol; 2005 Dec 20;23(36):9208-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).
  • PURPOSE: To perform an open-label, randomized, controlled trial comparing treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with two multidrug regimens (MDRs) for advanced Hodgkin's lymphoma (HL).
  • Patients receiving MDRs experienced more grade 3/4 infection, mucositis, and neuropathy.
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Chlorambucil / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Procarbazine / administration & dosage. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Dec 20;23(36):9058-62 [16314611.001]
  • (PMID = 16314615.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN97144519
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122861381
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 18D0SL7309 / Chlorambucil; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 9PHQ9Y1OLM / Prednisolone; ABVD protocol; ChlVPP protocol; PABlOE protocol
  •  go-up   go-down


66. Selvarajah V, Lake K, Robertson S, Carman W, Isles C, Scottish Renal Registry: Post-transplant lymphoproliferative disorder: case report and review of susceptibility to EBV in the Scottish adult renal transplant pool. NDT Plus; 2009 Feb;2(1):52-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-transplant lymphoproliferative disorder: case report and review of susceptibility to EBV in the Scottish adult renal transplant pool.
  • We report a case of high-grade non-Hodgkin's lymphoma following Epstein-Barr virus (EBV) infection in a 38-year-old renal transplant recipient who was successfully treated with rituximab and remains alive 6 years later with reasonable graft function.
  • We subsequently undertook a survey showing that 1.8% of the Scottish adult transplant pool are susceptible to EBV infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25949287.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4421486
  • [Keywords] NOTNLM ; CMV / EBV / PTLD / renal / transplantation
  •  go-up   go-down


67. Ryan GF, Roos DR, Seymour JF: Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma; 2006 Jan;6(4):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers.
  • The breast is an uncommon site of presentation for primary non-Hodgkin's lymphoma, with prognosis and patterns of relapse still not clearly defined.
  • Histology was predominantly intermediate grade, with diffuse large B-cell lymphoma (DLBL) in 16 cases (76%).
  • [MeSH-major] Breast Neoplasms / mortality. Lymphoma, B-Cell / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / prevention & control. Central Nervous System Neoplasms / secondary. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Treatment Failure

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507213.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


68. Phongkitkarun S, Varavithya V, Kazama T, Faria SC, Mar MV, Podoloff DA, Macapinlac HA: Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose. World J Gastroenterol; 2005 Dec 14;11(46):7284-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To demonstrate the (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) findings in patients with non-Hodgkinos lymphoma (NHL) involving the gastrointestinal (GI) tract and the clinical utility of modality despite of the known normal uptake of FDG in the GI tract.
  • RESULTS: Twenty-five patients had a high-grade lymphoma and eight had a low-grade lymphoma.
  • In high-grade lymphoma, PET showed focal nodular or diffuse hypermetabolic activity.
  • After the therapy, the patients whose biopsies showed no evidence of lymphoma had a lower uptake without focal lesions.
  • In patients whose post-treatment biopsies showed lymphoma, the SUV(max)+/-SD was 9.42+/-6.27.
  • Low-grade follicular lymphomas of the colon and stomach showed diffuse hypermetabolic activity in the bowel wall (SUV(max) 8.2 and 10.3, respectively).
  • The SUV(max) was 2.02-3.8 (mean 3.02) in the stomach lesions of patients with MALT lymphoma.
  • ONCLUSION: (18)F-FDG PET contributes to the diagnosis of high-grade gastrointestinal non-Hodgkin's lymphoma, even when there is the normal background FDG activity.
  • Low-grade NHL demonstrates FDG uptake but at a lesser intensity than seen in high-grade NHL.
  • [MeSH-major] Gastrointestinal Neoplasms / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437629.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC4725130
  •  go-up   go-down


69. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT, Wade JC, Chauncey T, Forman SJ, Lange T, Shizuru J, Langston A, Pulsipher MA, Sandmaier BM, Storb R, Maloney DG: Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol; 2008 Jan 10;26(2):211-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
  • PURPOSE: Few effective treatment options exist for chemotherapy-refractory indolent or transformed non-Hodgkin's lymphoma (NHL).
  • The incidences of grade 2 to 4 acute graft-versus-host disease (GVHD), grade 3 and 4 acute GVHD, and extensive chronic GVHD were 63%, 18%, and 47%, respectively.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056679.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA18029; United States / NHLBI NIH HHS / HL / K99-HL088021; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / P01 CA078902
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


70. Ozturk M, Komurcu S, Kilic S, Ozet A, Arpaci F, Ozturk B, Kuzhan O, Ataergin S: Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. Support Care Cancer; 2009 Oct;17(10):1295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient-reported scoring was performed according to a five-grade scale (0: no symptom; 1: mild; 2: moderate; 3: severe; 4: very severe).
  • The most frequent three diagnosis were non-Hodgkin's lymphoma (37%, n = 25), Hodgkin's lymphoma (12%, n = 8), and multiple myeloma (12%, n = 8).
  • RESULTS: All of the patients experienced mucositis at any grade.
  • [MeSH-minor] Adolescent. Adult. Aged. Carboplatin / administration & dosage. Carmustine / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Hodgkin Disease / therapy. Humans. Ifosfamide / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Male. Melphalan / administration & dosage. Middle Aged. Multiple Myeloma / therapy. Severity of Illness Index. Whole-Body Irradiation. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 May 1;100(9 Suppl):2026-46 [15108223.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1531-9 [14508842.001]
  • [Cites] Support Care Cancer. 2000 Jan;8(1):33-9 [10650895.001]
  • [Cites] J Clin Nurs. 2005 Jul;14(6):750-3 [15946283.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(29):7-15 [11694559.001]
  • [Cites] Support Care Cancer. 2006 Sep;14(9):974-6 [16502004.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):501-6 [16980998.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):875-85 [11550161.001]
  • [Cites] Bone Marrow Transplant. 1993 May;11(5):379-82 [8504271.001]
  • [Cites] Cancer. 2004 May 1;100(9 Suppl):1995-2025 [15108222.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5186-93 [16391299.001]
  • [Cites] Br J Haematol. 2000 Aug;110(2):292-9 [10971384.001]
  • [Cites] J Nutr. 2004 Nov;134(11):3207S-3209S [15514309.001]
  • [Cites] Lancet Oncol. 2003 Oct;4(10):595-604 [14554236.001]
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2590-8 [15602019.001]
  • (PMID = 19198890.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide; BEAM regimen; ICE protocol 3
  •  go-up   go-down


71. Al Zahrani A, Ibrahim N, Al Eid A: Rapid infusion rituximab changing practice for patient care. J Oncol Pharm Pract; 2009 Sep;15(3):183-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to explore the safety and tolerability of short infusion rituximab, (over 90 min), in Non-Hodgkin's lymphoma patients at Riyadh Military Hospital.
  • Adult oncology patients diagnosed with Non-Hodgkin's lymphoma, who were to receive rituximab, were included in the study.
  • In addition, all patients were advised to report any reaction occurring within 24 h after rituximab infusion.From April 2007 to September 2007, 21 patients with non-Hodgkin's lymphoma were treated with rituximab-based chemotherapy.
  • The 90-min Rituximab infusion schedule was well tolerated with no grade 3/4 infusion related adverse events observed.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Patient Care / trends
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Administration Schedule. Female. Humans. Infusions, Intravenous / methods. Male. Middle Aged. Rituximab. Time Factors

  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19171551.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


72. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, Moles MP, Bouabdallah K, Bulabois CE, Dupuis J, Rio B, Gratecos N, Yakoub-Agha I, Attal M, Tournilhac O, Decaudin D, Bourhis JH, Blaise D, Volteau C, Michallet M, Société Française de Greffe de Moëlle et de Thérapie Cellulaire: Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol; 2008 May 10;26(14):2264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.
  • PURPOSE: Aggressive T-cell lymphomas (ATCLs) represent 10% to 15% of non-Hodgkin's lymphomas (NHLs) in adults.
  • RESULTS: The different diagnosis included anaplastic large-cell lymphoma (ALCL; n = 27), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; n = 27), angioimmunoblastic T-cell lymphoma (AITL; n = 11), hepatosplenic gamma/delta lymphoma (HSL; n = 3), T-cell granular lymphocytic leukemia (T-GLL; n = 1), nasal natural killer (NK)/T-cell lymphoma (nasal-NK/L; n = 3) or non-nasal NK/T-cell lymphoma (non-nasal-NK/L; n = 2), enteropathy-type T-cell (n = 1), and human T-lymphotropic virus (HTLV)-1 lymphoma (n = 2).
  • In multivariate analysis, chemoresistant disease (stable, refractory, or progressing disease) at the time of alloSCT and the occurrence of severe grade 3 to 4 acute graft-versus-host disease (aGVHD) were the strongest adverse prognostic factors for OS (P = .03 and .03, respectively).
  • [MeSH-major] Graft vs Tumor Effect / immunology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Child. Disease-Free Survival. Female. Graft vs Host Disease / immunology. Humans. Male. Middle Aged. Retrospective Studies. Transplantation Conditioning. Transplantation, Homologous / immunology


73. Charfi S, Bahri Zouari I, Khabir A, Toumi N, Gouiaa N, Daoud J, Sellami Boudawara T: [Medullary compression revealing the presence of a follicular lymphoma: a case report]. Cancer Radiother; 2006 Dec;10(8):586-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Medullary compression revealing the presence of a follicular lymphoma: a case report].
  • Epidural localization is a rare presenting sign of non-Hodgkin's lymphoma.
  • Low grade lymphomas are rarely reported.
  • The histopathological study revealed a follicular lymphoma.
  • Our purpose is to describe the clinical features, the pathologic findings, the treatment and the prognosis of non-Hodgkin's lymphoma revealed by an epidural involvement.
  • [MeSH-major] Epidural Neoplasms / diagnosis. Lymphoma, Follicular / diagnosis. Spinal Cord Compression / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Epirubicin / therapeutic use. Female. Follow-Up Studies. Humans. Immunohistochemistry. Laminectomy. Magnetic Resonance Imaging. Prednisone / therapeutic use. Radiotherapy Dosage. Remission Induction. Spinal Cord / pathology. Thoracic Vertebrae. Time Factors. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16843028.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  •  go-up   go-down


74. Paydas S, Ergin M, Erdogan S, Seydaoglu G: Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leuk Res; 2008 Sep;32(9):1424-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas.
  • PATIENTS AND METHODS: One hundred seventy-seven cases (60 had low grade lymphoma (LGL), 117 had aggressive lymphoma (AL)) with NHL have been included in this analysis.
  • EBV positivity was associated with VEGF-A expression in diffuse large B cell lymphoma (DLBCL) (0.045).
  • [MeSH-major] Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Non-Hodgkin / metabolism. Vascular Endothelial Growth Factor A / metabolism. Viral Matrix Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18282597.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Viral Matrix Proteins
  •  go-up   go-down


75. Taylor PR, White JM, Prescott RJ, Angus B, Galloway MJ, Jackson GH, Lessells AM, Lucraft HH, Summerfield GP, Proctor SJ, Scotland And Newcastle Lymphoma Group: The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leuk Lymphoma; 2006 Nov;47(11):2321-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial.
  • Two hundred untreated patients with low grade NHL (KIEL), including 155 follicular NHL, were randomized to six courses of treatment with chlorambucil 20 mg m-2 for 3 days and dexamethasone 4 mg bd for 5 days (CD) vs the same regimen plus oral idarubicin 10 mg m-2 for 3 days (CID).
  • The Follicular Lymphoma International Prognostic Index (FLIPI) is confirmed as a good predictor of risk groups including a group of 23% with shorter survival.
  • [MeSH-major] Chlorambucil / therapeutic use. Dexamethasone / therapeutic use. Idarubicin / administration & dosage. Idarubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Disease Progression. Drug Therapy, Combination. England. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Time Factors. Treatment Failure

  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Nov;47(11):2267-8 [17107893.001]
  • (PMID = 17107904.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 7S5I7G3JQL / Dexamethasone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


81. Lebrun C, Bourg V, Tieulie N, Thomas P: Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol; 2009 Feb;16(2):246-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Rituximab, a chimeric IgG k monoclonal antibody that target CD20 is used for the treatment of relapsing/refractory CD20 positive low-grade non-Hodgkin's lymphoma and other autoimmune neuromuscular diseases.
  • Four previous short reports have described a good response of MG associated with lymphoma with rituximab.
  • It appears to be a promising and effective drug for the treatment of MG without lymphoma, with a substantial benefit to the clinical status and good tolerability.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cholinesterase Inhibitors / therapeutic use. Female. Humans. Immunoglobulins, Intravenous / therapeutic use. Immunosuppressive Agents / therapeutic use. Middle Aged. Rituximab

  • Genetic Alliance. consumer health - Myasthenia gravis.
  • MedlinePlus Health Information. consumer health - Myasthenia Gravis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19146644.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cholinesterase Inhibitors; 0 / Immunoglobulins, Intravenous; 0 / Immunologic Factors; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


82. Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, Kraut EH, Baiocchi RA, Moran ME, Johnson AJ, Schaaf LJ, Grever MR, Byrd JC: Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol; 2010 Jan 20;28(3):418-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
  • We conducted a phase I study of flavopiridol, fludarabine, and rituximab (FFR) in patients with mantle-cell lymphoma (MCL), indolent B-cell non-Hodgkin's lymphomas (B-NHL), and CLL to determine the activity of FFR.
  • RESULTS: Thirty-eight patients (median age, 62 years) with MCL (n = 10); indolent B-NHL including follicular (n = 9), marginal zone (n = 4), lymphoplasmacytic (n = 1), or small lymphocytic lymphoma (n = 3); and CLL (n = 11), were enrolled.
  • Two patients in cohort 2 developed grade 3 dose-limiting toxicity (seizures, renal insufficiency).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. B-Lymphocytes. Female. Flavonoids / administration & dosage. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoproliferative Disorders / drug therapy. Male. Middle Aged. Piperidines / administration & dosage. Rituximab. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Indolent B cell lymphoma.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):6012-8 [19826119.001]
  • [Cites] Blood. 2000 Jul 15;96(2):393-7 [10887097.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:207-21; discussion 221-2 [10911915.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6 Suppl 12):37-41 [11225999.001]
  • [Cites] Br J Haematol. 2002 Dec;119(4):976-84 [12472576.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1740-5 [12735303.001]
  • [Cites] Lancet. 2003 Jul 12;362(9378):139-46 [12867117.001]
  • [Cites] J Natl Cancer Inst. 1992 Nov 18;84(22):1736-40 [1279187.001]
  • [Cites] Biochem Pharmacol. 1993 Nov 17;46(10):1831-40 [8250970.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1580-9 [7888675.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1262-8 [8648382.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2973-8 [8674031.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3804-16 [9808574.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] Curr Opin Hematol. 2004 Nov;11(6):411-8 [15548996.001]
  • [Cites] Blood Rev. 2005 May;19(3):165-78 [15748964.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4003-8 [16946304.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Blood. 2008 Jan 15;111(2):558-65 [17962512.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2637-45 [18981292.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):376-87 [10699068.001]
  • (PMID = 20008633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA102276-01A1; United States / NCI NIH HHS / CA / U01 CA076576; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCI NIH HHS / CA / K23 CA102276; United States / NCI NIH HHS / CA / U01-CA76576
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Flavonoids; 0 / Piperidines; 45AD6X575G / alvocidib; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2815704
  •  go-up   go-down


83. Northup JK, Gadre SA, Ge Y, Lockhart LH, Velagaleti GV: Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition? Eur J Haematol; 2007 Feb;78(2):152-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first case is that of a lymph node sample from a 40-yr-old non-Hodgkin's lymphoma (NHL) patient sent for determination of disease progress.
  • Hematologic studies showed no evidence of transformation to high-grade NHL (>15% blasts with rare mitotic figures).
  • Cytogenetic studies of lymph node showed multiple clonal abnormalities, most notably a der(18) from a t(14;18) which is associated with high-grade NHL.
  • After two cycles of chemotherapy with fludarabine, the patient did not show any clinical response, suggesting possible progression to high-grade lymphoma.
  • The second case is of a patient with a history of human immunodeficiency virus and blastic natural killer leukemia/lymphoma.
  • Hematologic studies of ascitic fluid classified the patient as having pleural effusion lymphoma whereas bone marrow analysis showed no malignancy.
  • Bone marrow cytogenetic studies showed multiple clonal abnormalities including a t(8;14), which is commonly associated with Burkitt's lymphoma (BL).
  • To our knowledge, this is the first case wherein a morphologically normal bone marrow showed presence of clonal abnormalities consistent with BL or Pleural effusion lymphoma.
  • [MeSH-major] Burkitt Lymphoma / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Follicular / genetics. Lymphoma, Non-Hodgkin / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosomes, Human, Pair 12 / ultrastructure. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 18 / ultrastructure. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 8 / ultrastructure. Chromosomes, Human, X. Clone Cells / pathology. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm. Female. Genes, myc. Humans. Karyotyping. Lymph Nodes / pathology. Male. Mutagenesis, Insertional. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / pathology. Prednisone / administration & dosage. Rituximab. Trisomy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313561.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


84. Mohammadianpanah M, Omidvai S, Mosalei A, Ahmadloo N: Treatment results of tonsillar lymphoma: a 10-year experience. Ann Hematol; 2005 Apr;84(4):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of tonsillar lymphoma: a 10-year experience.
  • Primary extranodal non-Hodgkin's lymphomas of the head and neck account for 10-20% of all non-Hodgkin's lymphomas.
  • Primary tonsillar lymphoma accounts for less than 1% of head and neck malignancies, although the tonsil is the most common primary extranodal site of head and neck non-Hodgkin's lymphomas.
  • In this study we analyzed our cases of tonsillar lymphoma treated in our institution during the last 10 years to compare the finding of this study with those of previous studies.
  • We reviewed the cases of tonsillar lymphoma treated in the Radiation Oncology Department of Shiraz University from 1992 to 2002.
  • High-grade tumors seemed to affect mainly young people (p=0.226).
  • Three patients (16%) experienced grade 3 or 4 neutropenia.
  • Mild (grade I) xerostomia remained persistently in four patients (21%).
  • A late fatal side effect was observed in one patient who developed radiation-induced sarcoma 7 years after initial diagnosis and died 8 months later without evidence of recurrent lymphoma.
  • Combined chemotherapy and radiation therapy is safe, highly effective, and probably curative for most patients with primary tonsillar lymphoma.
  • [MeSH-major] Combined Modality Therapy / methods. Lymphoma, Non-Hodgkin / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Follow-Up Studies. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant / adverse effects. Remission Induction / methods. Retrospective Studies. Risk Factors. Survival Rate. Tonsillectomy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15042316.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Buhmann R, Simoes B, Stanglmaier M, Yang T, Faltin M, Bund D, Lindhofer H, Kolb HJ: Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant; 2009 Mar;43(5):383-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Donor lymphocyte infusions (DLIs) after allo-SCT displayed limited use in CLL and highly malignant non-Hodgkin's lymphoma (NHL).
  • Here we studied whether Bi20 (FBTA05), a novel trifunctional bispecific antibody targeting CD20 on lymphoma cells and CD3 on T cells, could induce GVL responses in combination with DLI or mobilized PBSCT after allogeneic transplantation in these diseases.
  • Six patients (three cases with p53-mutated CLL and three with high-grade NHL (HG-NHL)) refractory to standard therapy were treated with escalating doses of Bi20 (range 10-2000 microg) followed by DLI or SCT.
  • [MeSH-major] Adoptive Transfer. Antibodies, Bispecific / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Female. Graft vs Host Disease / etiology. Humans. Male. Middle Aged. Pilot Projects. Recurrence. Tissue Donors. Transplantation, Homologous

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18850012.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Bi20 antibody
  •  go-up   go-down


86. Hashino S, Morioka M, Irie T, Shiroshita N, Kawamura T, Suzuki S, Iwasaki H, Umehara S, Kakinoki Y, Kurosawa M, Kahata K, Izumiyama K, Kobayashi H, Onozawa M, Takahata M, Fujisawa F, Kondo T, Asaka M: Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma. Int J Lab Hematol; 2008 Aug;30(4):292-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
  • High costs of molecule-targeted drugs, such as rituximab, ibritumomab, and tositumomab have given rise to an economical issue for treating patients with non-Hodgkin's lymphoma (NHL).
  • Frequencies and durations of grade 4 leukocytopenia and neutropenia were similar in the two groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Granulocyte Colony-Stimulating Factor / economics. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cost-Benefit Analysis. Cross-Over Studies. Female. Filgrastim. Humans. Male. Middle Aged. Neutropenia / drug therapy. Neutropenia / etiology. Recombinant Proteins / administration & dosage. Recombinant Proteins / economics

  • Hazardous Substances Data Bank. Filgrastim .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665826.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6WS4C399GB / lenograstim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


87. Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol; 2008 Jan 1;26(1):90-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
  • PURPOSE: This phase II trial evaluated the safety and efficacy of combining yttrium-90 (90Y) ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (BEAM) and autologous stem-cell transplantation in patients with non-Hodgkin's lymphoma who were considered ineligible for total-body irradiation because of older age or prior radiotherapy.
  • PATIENTS AND METHODS: Between May 2002 and January 2006, 14 days before autologous stem-cell transplantation, 41 patients with non-Hodgkin's lymphoma received standard-dose 90Y ibritumomab tiuxetan (14.8 MBq/kg [0.4 mCi/kg]) followed by high-dose BEAM.
  • Disease histologies were diffuse large B-cell (n = 20), mantle cell (n = 13), follicular (n = 4), and transformed lymphoma (n = 4).
  • Adverse events were similar to those seen historically with high-dose BEAM alone, and included grade 3 or 4 pulmonary toxicity in 10 patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy. Stem Cell Transplantation. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Carmustine / therapeutic use. Combined Modality Therapy. Cytarabine / therapeutic use. Disease-Free Survival. Female. Humans. Lymphoma, Follicular / pathology. Lymphoma, Follicular / therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Mantle-Cell / pathology. Lymphoma, Mantle-Cell / therapy. Male. Melphalan / therapeutic use. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Podophyllotoxin / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. PODOFILOX .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18025438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR0043; United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P30CA3357
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 04079A1RDZ / Cytarabine; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM protocol
  •  go-up   go-down


88. Klimm B, Eich HT, Haverkamp H, Lohri A, Koch P, Boissevain F, Trenn G, Worst P, Dühmke E, Müller RP, Müller-Hermelink K, Pfistner B, Diehl V, Engert A, German Hodgkin Study Group: Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol; 2007 Feb;18(2):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.
  • BACKGROUND: The optimal treatment of elderly patients with Hodgkin's lymphoma (HL) is still a matter of debate.
  • Acute toxicity from RT was more pronounced in elderly patients receiving EF-RT compared with IF-RT [World Health Organization (WHO) grade 3/4: 26.5% versus 8.6%)].

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071932.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


89. Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD: Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol; 2008 Sep 20;26(27):4473-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
  • PURPOSE: Bendamustine HCl is a bifunctional mechlorethamine derivative with clinical activity in the treatment of non-Hodgkin's lymphoma.
  • This study evaluated bendamustine plus rituximab in 67 adults with relapsed, indolent B-cell or mantle cell lymphoma without documented resistance to prior rituximab.
  • The combination was generally well tolerated; the primary toxicity was myelosuppression (grade 3 or 4 neutropenia, 36%; grade 3 or 4 thrombocytopenia, 9%).
  • CONCLUSION: Bendamustine plus rituximab is an active combination in patients with relapsed indolent and mantle cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nitrogen Mustard Compounds / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Bendamustine Hydrochloride. Female. Gastrointestinal Diseases / chemically induced. Headache / chemically induced. Hematologic Diseases / chemically induced. Humans. Infection / chemically induced. Kaplan-Meier Estimate. Male. Middle Aged. Nausea / chemically induced. Remission Induction. Rituximab


90. García Ortiz LM, Jaume Anselmi F, Ramírez Rivera J, Casiano Quiles W, Márquez Santiago R: Non-Hodgkin's lymphoma presenting as ulcerative colitis. Bol Asoc Med P R; 2006 Apr-Jun;98(2):140-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as ulcerative colitis.
  • High-grade Non-Hodgkin's lymphomas are very aggressive type of malignancies.
  • We report a high grade small B-cell (Burkitt's like) Non-Hodgkin's lymphoma that initially was considered and treated as ulcerative colitis without improvement or resolution of symptoms for nine months.
  • [MeSH-major] Colitis, Ulcerative / etiology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606804.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


91. Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima Y: Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci; 2008 Jan;99(1):179-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • The management of relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) remains challenging.
  • The treatment was generally well tolerated, with major toxicities being grade 4 neutropenia (n = 32), thrombocytopenia requiring transfusion (n = 28), and grade 3 transaminase elevation (n = 2).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Hematopoietic Stem Cell Mobilization. Humans. Immunotherapy / methods. Middle Aged. Rituximab. Stem Cell Transplantation

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991293.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


92. Tiwari D, Gao F, Hidalgo J, Adkins DR, Vij R, DiPersio JF, Khoury HJ: Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant; 2007 Oct;40(7):671-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma.
  • The purpose of this study was to analyze the prognostic significance of early lymphocyte recovery after autologous SCT (ASCT) in the setting of routine post transplant administration of GM-CSF in patients with non-Hodgkin's lymphoma (NHL).
  • With a median follow-up of 22 months, no associations between early lymphocyte recovery and improvement of disease-free and overall survival were observed for either low- or intermediate-grade NHL.
  • [MeSH-major] Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Lymphocyte Count. Lymphocytes / immunology. Lymphoma, Non-Hodgkin / therapy. Platelet Transfusion. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Antigens, CD / blood. Antigens, CD34 / blood. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neutropenia / epidemiology. Prognosis. Retrospective Studies. Transplantation, Autologous. Treatment Outcome

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680023.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


93. Danzon A, Belot A, Maynadié M, Remontet L, Dupont AC, Carbonnel F, Association FRANCIM: Incidence and survival of gastric non-Hodgkin's lymphoma: a population-based study from the Association of the French Cancer Registries (FRANCIM). Acta Oncol; 2009;48(7):977-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and survival of gastric non-Hodgkin's lymphoma: a population-based study from the Association of the French Cancer Registries (FRANCIM).
  • Effects specific to sex, age at diagnosis, year of diagnosis, and grade of malignancy were estimated in multivariate analysis.
  • However, high-grade GL frequency increased whereas low-grade and not otherwise specified (NOS) GL frequencies were respectively stable and decreased.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Registries / statistics & numerical data. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age of Onset. Aged. Female. France / epidemiology. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Risk Factors. Sex Distribution. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19551530.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


94. Chiang J, Chan A, Shih V, Hee SW, Tao M, Lim ST: A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center. Int J Hematol; 2010 Jun;91(5):826-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rituximab (Mabthera) is currently approved for the treatment of multiple subtypes of CD20-expressing, B-cell, non-Hodgkin's lymphoma.
  • Lymphoma patients who have received one cycle of rituximab without experiencing grade 3 or 4 infusional reaction were eligible for the rapid infusion of rituximab.
  • Rapid rituximab infusion schedule was well tolerated without any grade 3/4 infusion-related adverse events observed.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Asia. Female. Humans. Male. Middle Aged. Prospective Studies. Rituximab. Time Factors. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] Eur J Haematol. 2009 Apr;82(4):322-5 [19220420.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):1027-8 [16322113.001]
  • [Cites] J Natl Compr Canc Netw. 2010 Mar;8(3):288-334 [20202462.001]
  • [Cites] Eur J Haematol. 2006 Oct;77(4):338-40 [16856919.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7935-9 [19047125.001]
  • [Cites] Blood. 2007 May 15;109(10):4171-3 [17244675.001]
  • (PMID = 20461562.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


95. Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol; 2005 Feb 1;23(4):694-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
  • PURPOSE: To evaluate the safety and efficacy of fludarabine plus rituximab in treatment-naive or relapsed patients with low-grade and/or follicular non-Hodgkin's lymphoma.
  • CONCLUSION: Rituximab plus fludarabine was well tolerated and associated with an excellent complete response rate, including molecular remissions, in patients with low-grade or follicular lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Flow Cytometry. Genes, bcl-2. Humans. Male. Middle Aged. Rituximab. T-Lymphocyte Subsets / immunology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15681517.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


96. Omoti CE, Halim NK: Adult lymphomas in Edo state, Niger Delta region of Nigeria--clinicopathological profile of 205 cases. Clin Lab Haematol; 2005 Oct;27(5):302-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult lymphomas in Edo state, Niger Delta region of Nigeria--clinicopathological profile of 205 cases.
  • Non-Hodgkin's lymphoma (NHL) occurred predominantly in young adults (20-39 years).
  • The intermediate grade NHL (41.2%) formed the largest group of which diffuse large cell lymphoma (DLCL) was the most commonly observed histopathologic type followed by the large cell immunoblastic type.
  • [MeSH-major] Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Female. Hematologic Tests. Hodgkin Disease / diagnosis. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Neoplasm Staging. Nigeria / epidemiology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178909.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD: Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol; 2008 Jan 10;26(2):204-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
  • This phase II multicenter study evaluated the efficacy and toxicity of bendamustine in patients with B-cell non-Hodgkin's lymphoma (NHL) refractory to rituximab.
  • Grade 3 or 4 reversible hematologic toxicities included neutropenia (54%), thrombocytopenia (25%), and anemia (12%).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Nitrogen Mustard Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Bendamustine Hydrochloride. Female. Humans. Male. Middle Aged. Rituximab. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2008 Apr 10;26(11) 1911
  • (PMID = 18182663.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-102216
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Nitrogen Mustard Compounds; 4F4X42SYQ6 / Rituximab; 981Y8SX18M / Bendamustine Hydrochloride
  •  go-up   go-down


98. Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM: The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol; 2005 Oct;32(9):616-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
  • BACKGROUND: Rituximab has been used to treat relapsed low-grade or advanced non-Hodgkin's lymphoma since 1997, targeting the CD20 antigen expressed by B cells.
  • METHODS: Four patients with CD20-positive cutaneous B-cell lymphoma received rituximab therapy with subsequent recurrences.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / metabolism. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Neoplasm Recurrence, Local / metabolism. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176299.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


99. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, Diehl V, Raubitschek A, Engert A: Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol; 2005 Jul 20;23(21):4669-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
  • PURPOSE: Hodgkin's lymphoma (HL) has been demonstrated to be a good target for immunotherapy since lymphocyte activation markers such as CD30 are expressed in high numbers on the malignant cells.
  • Acute toxicity was mild with grade 1 fatigue in 19 of 22 assessable patients.
  • Seven patients experienced grade 4 degrees hematotoxicity 4 to 8 weeks after treatment.
  • [MeSH-minor] Adolescent. Adult. Animals. Humans. Iodine Radioisotopes. Mice. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034043.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD30; 0 / Immunoconjugates; 0 / Iodine Radioisotopes
  •  go-up   go-down


100. Wu Y, Liu WL, Sun HY, Xu HZ: [Expression of P120ctn in non-Hodgkin's lymphoma and its significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun;14(3):508-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of P120ctn in non-Hodgkin's lymphoma and its significance].
  • To evaluate the expression of P120ctn in non-Hodgkin's lymphoma (NHL) and to explore its clinical significance, immunohistochemistry stain method was applied to comparatively investigate the protein expression of P120ctn in paraffin-embedded lymph node tissue slices from 40 cases of NHL and 10 cases of reactive hyperplasia of lymph node.
  • P120ctn expression increased with the tumor malignancy of NHL, there was a significant difference between the expression rates of P120ctn in low grade (16.7%, 2/12) and intermediate to high grade malignant (71.4%, 20/28) NHL (P < 0.001).
  • It is concluded that the level of P120ctn expression is closely related to the malignant grade of NHL, it suggests that P120ctn possibly plays an important role in the malignant proliferation of lymphoma with a certain significance in diagnosis and therapy of lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800931.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Catenins; 0 / Cell Adhesion Molecules; 0 / Phosphoproteins; 0 / delta catenin
  •  go-up   go-down






Advertisement